10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 _______________________________________

FORM 10-Q

 ___________________________________________

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended September 30, 2012

OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from              to               .

Commission File Number 001-33124

 ___________________________________________

INNOPHOS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

 ___________________________________________

Delaware	20-1380758
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
259 Prospect Plains Road Cranbury, New Jersey	08512
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (609) 495-2495

 ____________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  o    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	x	Accelerated Filer	o
Non-accelerated filer	o	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x

As of September 30, 2012, the registrant had 21,719,965 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
PART I
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	31
PART II
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	32
Signatures		33

Page 2 of 34

PART I

ITEM 1. FINANCIAL STATEMENTS

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

	September 30, 2012			December 31, 2011
ASSETS
Current assets:
Cash and cash equivalents	$	36,571		$	35,242
Accounts receivable, net	93,984			104,421
Inventories	154,240			169,728
Other current assets	78,493			75,316
Total current assets	363,288			384,707
Property, plant and equipment, net	185,876			187,421
Goodwill	68,047			61,587
Intangibles and other assets, net	60,069			53,300
Total assets	$	677,280		$	687,015
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt	$	4,000		$	4,000
Accounts payable, trade and other	35,861			32,640
Other current liabilities	48,508			71,609
Total current liabilities	88,369			108,249
Long-term debt	113,000			148,000
Other long-term liabilities	36,866			37,558
Total liabilities	$	238,235		$	293,807
Commitments and contingencies (note 12)
Common stock, par value $.001 per share; authorized 100,000,000 shares; issued 22,020,597 and 21,770,641 shares; outstanding 21,719,965 and 21,620,119 shares	22			22
Paid-in capital	115,792			112,193
Common stock held in treasury, at cost (300,632 and 150,522 shares)	(13,411		)	(6,156		)
Retained earnings	340,961			292,144
Accumulated other comprehensive loss	(4,319		)	(4,995		)
Total stockholders' equity	439,045			393,208
Total liabilities and stockholders' equity	$	677,280		$	687,015

See notes to condensed consolidated financial statements

Page 3 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

	Three months ended						Nine months ended
	September 30, 2012			September 30, 2011			September 30, 2012			September 30, 2011
Net sales	$	211,188		$	202,102		$	653,620		$	601,327
Cost of goods sold	168,409			152,872			512,605			445,604
Gross profit	42,779			49,230			141,015			155,723
Operating expenses:
Selling, general and administrative	17,417			15,343			49,687			46,954
Research & development expenses	776			762			2,320			2,205
Total operating expenses	18,193			16,105			52,007			49,159
Operating income	24,586			33,125			89,008			106,564
Interest expense, net	1,314			1,502			4,536			4,087
Foreign exchange (gains) losses	(1,800		)	1,459			(2,199		)	2,017
Income before income taxes	25,072			30,164			86,671			100,460
Provision for income taxes	8,366			11,307			25,873			34,888
Net income	$	16,706		18,857			$	60,798		65,572
Net income attributable to common shareholders	$	16,695		$	18,857		$	60,758		$	65,572
Per share data (note 2):
Income per share:
Basic	$	0.77		$	0.87		$	2.79		$	3.02
Diluted	$	0.74		$	0.84		$	2.70		$	2.90
Weighted average shares outstanding:
Basic	21,807,013			21,691,892			21,804,415			21,719,580
Diluted	22,500,262			22,557,661			22,519,360			22,604,845
Other comprehensive income (loss), net of tax:
Change in interest rate swaps, (net of tax $136, ($230), $312 and ($589))	$	221		$	(375	)	$	509		$	(962	)
Change in pension and post-retirement plans, (net of tax ($18), $76, $70 and $319)	(80		)	223			167			652
Other comprehensive income (loss), net of tax	$	141		$	(152	)	$	676		$	(310	)
Comprehensive income	$	16,847		$	18,705		$	61,474		$	65,262

See notes to condensed consolidated financial statements

Page 4 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

	Nine months ended
	September 30, 2012			September 30, 2011
Cash flows from operating activities
Net income	$	60,798		$	65,572
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	32,118			32,443
Amortization of deferred financing charges	428			461
Deferred income tax (benefit) provision	(1,545		)	6,378
Deferred profit sharing	—			395
Share-based compensation	3,319			5,122
Changes in assets and liabilities:
Decrease (increase) in accounts receivable	11,278			(10,870		)
Decrease (increase) in inventories	17,508			(34,747		)
(Increase) decrease in other current assets	(3,138		)	9,503
Increase (decrease) in accounts payable	2,844			(443		)
(Decrease) increase in other current liabilities	(18,933		)	4,731
Changes in other long-term assets and liabilities	(3,884		)	(3,111		)
Net cash provided from operating activities	100,793			75,434
Cash flows used for investing activities:
Capital expenditures	(15,997		)	(27,247		)
Investment in AMT	(27,093		)	—
Net cash used for investing activities	(43,090		)	(27,247		)
Cash flows used for financing activities:
Proceeds from exercise of stock options	381			484
Long-term debt borrowings	15,000			—
Long-term debt repayments	(50,000		)	(8,000		)
Excess tax benefits from exercise of stock options	2,681			2,487
Common stock repurchases	(7,255		)	(6,156		)
Dividends paid	(17,181		)	(14,517		)
Net cash used for financing activities	(56,374		)	(25,702		)
Net change in cash	1,329			22,485
Cash and cash equivalents at beginning of period	35,242			63,706
Cash and cash equivalents at end of period	$	36,571		$	86,191

See notes to condensed consolidated financial statements

Page 5 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Statement of Stockholders’ Equity (Unaudited)

(Dollars and shares in thousands)

	Number of Common Shares		Common Stock		Retained Earnings			Paid-in Capital			Accumulated Other Comprehensive Income/(Loss)			Total Shareholders' Equity
Balance, December 31, 2010	21,464		$	21	$	227,752		$	106,032		$	(3,089	)	$	330,716
Net income					86,522									86,522
Other comprehensive loss, (net of tax $836)											(1,906		)	(1,906		)
Proceeds from stock award exercises and issuances	300		1					(2,600		)				(2,599		)
Issuance of annual retainer stock to external Board of Directors	7													—
Share-based compensation								6,250						6,250
Excess tax benefits from exercise of stock options								2,511						2,511
Common stock repurchases	(151	)						(6,156		)				(6,156		)
Dividends declared					(22,130		)							(22,130		)
Balance, December 31, 2011	21,620		$	22	$	292,144		$	106,037		$	(4,995	)	$	393,208
Net income					60,798									60,798
Other comprehensive income, (net of tax $382)											676			676
Proceeds from stock award exercises and issuances	250							(2,401		)				(2,401		)
Share-based compensation								3,319						3,319
Excess tax benefits from exercise of stock options								2,681						2,681
Common stock repurchases	(150	)						(7,255		)				(7,255		)
Dividends declared					(11,981		)							(11,981		)
Balance, September 30, 2012	21,720		$	22	$	340,961		$	102,381		$	(4,319	)	$	439,045

See notes to condensed consolidated financial statements

Page 6 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

1. Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2011 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2011 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

Out of Period Adjustments

During the second quarter of fiscal 2012, we identified certain adjustments in our financial statements related to 2011 through the first quarter of fiscal 2012. We corrected the items during the second quarter of fiscal 2012, which had the effect of increasing cost of goods sold by $3.9 million, and decreasing net income by $2.6 million. The impact of these items for the nine months ended September 30, 2012 increased cost of goods sold by $2.4 million and decreased net income by $1.6 million. These prior period adjustments are not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. These adjustments are also not expected to be material to the full year 2012 financial statements.

Recently Issued Accounting Standards

Adopted

In May 2011, the FASB issued changes to conform existing guidance regarding fair value measurement and disclosure between U.S. GAAP and International Financial Reporting Standards. These changes both clarify the FASB's intent about the application of existing fair value measurement and disclosure requirements and amend certain principles or requirements for measuring fair value or for disclosing information about fair value measurements. The clarifying changes relate to the application of the highest and best use and valuation premise concepts, measuring the fair value of an instrument classified in a reporting entity's shareholders' equity, and disclosure of quantitative information about unobservable inputs used for Level 3 fair value measurements. The amendments relate to measuring the fair value of financial instruments that are managed within a portfolio; application of premiums and discounts in a fair value measurement; and additional disclosures concerning the valuation processes used and sensitivity of the fair value measurement to changes in unobservable inputs for those items categorized as Level 3, a reporting entity's use of a nonfinancial asset in a way that differs from the asset's highest and best use, and the categorization by level in the fair value hierarchy for items required to be measured at fair value for disclosure purposes only. These changes become effective for the Company on January 1, 2012. The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.

In September 2011, the FASB issued amendments to the goodwill impairment guidance which provides an option for companies to use a qualitative approach to test goodwill for impairment if certain conditions are met. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 (early adoption is permitted). The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.

Issued but not yet adopted

In July 2012, the Financial Accounting Standards Board issued updated guidance on the periodic testing of indefinite-lived intangible assets for impairment. The updated guidance gives companies the option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount and, thus, whether further impairment testing is necessary. The updated accounting guidance is effective for fiscal years beginning after

Page 7 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

September 15, 2012, with early adoption permitted. The implementation of this standard will not have a material impact on the Company's consolidated financial position and results of operations.

2. Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended					Nine Months Ended
	September 30, 2012			September 30, 2011		September 30, 2012			September 30, 2011
Net income	$	16,706		$	18,857	$	60,798		$	65,572
Less: earnings attributable to unvested shares	(11		)	—		(40		)	—
Net income available to common shareholders	$	16,695		$	18,857	$	60,758		$	65,572
Weighted average number of common and potential common shares outstanding:
Basic number of common shares outstanding	21,807,013			21,691,892		21,804,415			21,719,580
Dilutive effect of stock equivalents	693,249			865,769		714,945			885,265
Diluted number of weighted average common shares outstanding	22,500,262			22,557,661		22,519,360			22,604,845
Earnings per common share:
Earnings per common share—Basic	$	0.77		$	0.87	$	2.79		$	3.02
Earnings per common share—Diluted	$	0.74		$	0.84	$	2.70		$	2.90
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	387,878			422,734		366,182			403,238

Page 8 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

3. Dividends

The following is the dividend activity for the three and nine months ended September 30, 2012 and September 30, 2011:

	Three Months Ended				Nine Months Ended
	September 30				September 30
	2012		2011		2012		2011
Dividends declared – per share	$	—	$	0.25	$	0.54	$	0.75
Dividends declared – aggregate	—		5,442		11,776		16,309
Dividends paid – per share	0.27		0.25		0.79		0.67
Dividends paid – aggregate	5,891		5,442		17,181		14,517

We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.

On October 26, 2012, the Company's Board of Directors declared an increase to its dividend to $0.35 per share to be paid on November 30, 2012 to shareholders of record on November 16, 2012.

4. Stockholders’ Equity / Stock-Based Compensation

Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:

• Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.

• Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.

Restricted Stock

On March 30, 2012 there were a total of 14,370 restricted shares granted to certain employees with a fair value of $0.7 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $50.12. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.

Stock Options

On March 30, 2012 the Company granted 39,683 non-qualified stock options at an exercise price of $50.12 per share to certain employees with a fair value of $0.8 million. The non-qualified stock options vest annually over three years with a March 30, 2022 expiration date.

The fair value of the options granted during 2012 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Page 9 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Non-qualified stock options
Expected volatility	53.2		%
Dividend yield	2.4		%
Risk-free interest rate	1.3		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	20.41

For the 2012 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.

Performance Share Awards

On March 30, 2012, the Company granted 43,106 performance shares to certain employees with a fair value of $2.2 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.

In connection with the vesting of the performance share awards issued in 2009, the Company issued 136,423 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2012.

Stock Grants

In May 2012 the six external members of the Board of Directors were each granted 1,275 shares of the Company's common stock with an aggregated fair value of $0.4 million which immediately vested as part of their director fees.

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended				Nine Months Ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Stock options	$	291	$	288	$	1,147	$	1,225
Restricted stock	57		—		180		6
Performance shares	643		806		1,632		3,591
Stock grants	—		—		360		300
Total share-based compensation expense	$	991	$	1,094	$	3,319	$	5,122

During 2011 the Board of Directors authorized a repurchase program for Company common stock of up to $50 million. Under the program, shares will be repurchased from time to time at management's discretion, either through open market transactions, block purchases, private transactions or other means and will be funded through existing liquidity and cash from operations. A five year time limit has been set for the expiration of the program as initially structured. The timing of repurchases and the exact number of shares of common stock to be purchased will depend upon market conditions and other factors. However, annual repurchase amounts are expected at a minimum to be sufficient to reduce significantly, or eliminate, earnings per share dilution caused by shares issued upon the exercise of stock options and in connection with other equity based compensation plans. Treasury stock is recognized at the cost to reacquire the shares. During the third quarter of 2012, the

Page 10 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Company repurchased 150,000 shares of its common stock on the open market at an average price of $48.37 per share or $7.3 million.

5. Inventories

Inventories consist of the following:

	September 30, 2012		December 31, 2011
Raw materials	$	39,454	$	44,937
Finished products	105,878		116,488
Spare parts	8,908		8,303
	$	154,240	$	169,728

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of September 30, 2012 and December 31, 2011 were $11,849 and $9,911, respectively.

6. Other Current Assets

Other current assets consist of the following:

	September 30, 2012		December 31, 2011
Rhodia indemnity receivable for CNA water tax claims (see note 12)	$	—	$	13,571
Creditable taxes (value added taxes)	31,957		20,473
Vendor inventory deposits (prepaid)	12,036		19,671
Prepaid income taxes	17,324		4,829
Other prepaids	2,397		2,585
Deferred income taxes	10,348		10,347
Other	4,431		3,840
	$	78,493	$	75,316

Page 11 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

7. Intangibles and Other Assets, net

Intangibles and other assets consist of the following:

	Useful life (years)	September 30, 2012		December 31, 2011
Developed technology and application patents, net of accumulated amortization of $15,585 for 2012 and $13,980 for 2011	7-20	$	24,305	$	24,010
Customer relationships, net of accumulated amortization of $7,203 for 2012 and $5,956 for 2011	5-15	18,907		13,333
Tradenames and license agreements, net of accumulated amortization of $4,676 for 2012 and $4,246 for 2011	5-20	6,474		5,974
Non-compete agreements, net of accumulated amortization of $636 for 2012 and $568 for 2011	5-10	184		73
Total intangibles		$	49,870	$	43,390
Deferred financing costs, net of accumulated amortization of $1,265 for 2012 and $837 for 2011 (see note 9)		$	1,563	$	1,991
Deferred income taxes		5,768		5,450
Other Assets		2,868		2,469
Total other assets		$	10,199	$	9,910
		$	60,069	$	53,300

8. Other Current Liabilities

Other current liabilities consist of the following:

	September 30, 2012		December 31, 2011
CNA water tax claims (see Note 12)	$	10,592	$	31,523
Payroll related	10,820		11,708
Taxes	9,292		5,885
Benefits and pensions	5,884		7,717
Freight and rebates	4,962		4,418
Dividends payable	—		5,405
Other	6,958		4,953
	$	48,508	$	71,609

9. Short-term Borrowings, Long-Term Debt, and Interest Expense

Short-term borrowings and long-term debt consist of the following:

	September 30, 2012		December 31, 2011
Term loan due 2015	$	92,000	$	95,000
Revolver borrowings under the credit facility	25,000		57,000
Total borrowings	$	117,000	$	152,000
Less current portion	4,000		4,000
Long-term debt	$	113,000	$	148,000

The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $125.0 million, including a $20.0 million letter of credit sub-facility, all maturing on August 26, 2015. Prepayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on December 31, 2010.

As of September 30, 2012, $92.0 million was outstanding under the Term Loan and $25.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, level 2 input within

Page 12 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

the fair value hierarchy, with total availability at $98.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 4.1%.

In the third quarter of 2010 the Company entered into an interest rate swap with an original notional amount of $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 1.994% plus the applicable margin on the debt expiring in August 2015. The Company exercised its right to cancel the interest rate swap with no fee on September 28, 2012.

We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.

Total interest paid by the Company for all indebtedness for the nine months ended September 30, 2012 and September 30, 2011 was $4,355 and $4,504.

As of September 30, 2012, the Company was in full compliance with all debt covenant requirements.

Interest expense, net consists of the following:

	Three months ended						Nine months ended
	September 30, 2012			September 30, 2011			September 30, 2012			September 30, 2011
Interest expense	$	1,371		1,478			$	4,350		4,475
Deferred financing cost	141			149			428			461
Interest income	(11		)	(98		)	(55		)	(403		)
Less: amount capitalized for capital projects	(187		)	(27		)	(187		)	(446		)
Total interest expense, net	$	1,314		$	1,502		$	4,536		$	4,087

10. Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	September 30, 2012		December 31, 2011
Deferred income taxes	$	23,761	$	24,308
Pension and post retirement liabilities (U.S. and Canada only)	6,290		6,185
Environmental liabilities	1,100		1,100
Profit sharing and post employment liabilities	4,478		3,795
Other liabilities	1,237		2,170
	$	36,866	$	37,558

11. Income Taxes

The effective income tax rate on income before taxes was approximately 30% for the nine months ended September 30, 2012 compared to approximately 35% for the comparable period in 2011. The variance in the effective tax rate is primarily due to the recording of an indemnity receivable related to the Mexican CNA Water Tax Claims (see note 12, Mexican CNA Water Tax Claims) being recorded as a discrete item for income tax provision purposes in the first quarter of 2012.

The Company does not have any material uncertain income tax positions in accordance with ASC 740-10-25. If any material uncertain tax positions did arise, the Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2009. As of September 30, 2012, our subsidiary, Innophos Mexicana requested a refund of $2.4 million for the 2009 tax year which is being disputed by the Mexican tax authorities. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. On April 27, 2012, Innophos Canada filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. Other than

Page 13 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

the assessments mentioned above, as of September 30, 2012, no significant adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.

Income taxes paid were $36,931 and $17,543 for the nine months ended September 30, 2012 and September 30, 2011, respectively.

12. Commitments and Contingencies

Environmental

The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Liabilities for environmental matters are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.

Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of September 30, 2012.

Litigation

2008 RCRA Civil Enforcement – Geismar, Louisiana plant

Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.

Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.

In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is ready for commissioning and operation once appropriate agreements are reached with the Government Parties and PCS.

We and PCS also have initiated joint efforts to explore possible technical solutions to remaining concerns of the Government Parties, including Raffinate treatment. To date, treatment techniques for Raffinate have not yet been fully evaluated from a technological or cost standpoint. Based upon work so far, there appears to be at least one technically viable approach, but it has yet to be fully evaluated.

Page 14 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Even though the companies have conducted substantial technical work in an attempt to develop a feasible approach to address regulatory concerns, we cannot guarantee that our technical efforts will be successful, whether either party would be willing to implement solutions at what cost allocation or, depending on those factors and the Government Parties' position, whether this matter will be settled or will require litigation. Should litigation become necessary to defend our operations at Geismar as compliant with environmental laws and regulations or with PCS as to cost responsibility, no assurance can be given as to its outcome.

Based upon advice of our environmental counsel, we have determined that the risk of an effort by the Government Parties to shut down our Geismar plant or PCS's Geismar plant from which we obtain the green acid raw material is remote. In addition, we have concluded that the contingent liability arising from compliance costs for this matter as discussed above is neither remote nor probable, but is reasonably possible. On the assumption that “deep well injection” at the site is ultimately employed or required as the technologically acceptable approach for Raffinate, based on preliminary cost estimates to date, we estimate this technical approach to range from approximately $10 to $16 million.

Mexican CNA Water Tax Claims - 2005-2008

In January 2012, Fosfatados was served with CNA resolutions claiming higher water fees, surcharges and penalties for 2005 through 2008 for the total amount of approximately $10.6 million at current exchange rates (net of regulatory discounts), for which the Company has recorded an accrual. The Company has timely contested the resolutions in Mexican Courts and posted security for the amount claimed by granting liens, in accordance with Mexican law, on specified production assets located at its Coatzacoalcos plant.

Other Legal Matters

In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.

In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters currently represent contingent liabilities that are not material. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.

Page 15 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

13. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

	For the three months ended September 30, 2012									For the three months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	81		$	81		$	—		$	72		$	72
Interest cost	28			34			62			27			37			64
Expected return on assets	(28		)	—			(28		)	(18		)	—			(18		)
Amortization of
prior service cost	—			33			33			—			32			32
unrecognized (gain) loss	4			(7		)	(3		)	—			(15		)	(15		)
Net periodic cost	$	4		$	141		$	145		$	9		$	126		$	135
	For the nine months ended September 30, 2012									For the nine months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	243		$	243		$	—		$	219		$	219
Interest cost	82			106			188			83			111			194
Expected return on assets	(82		)	—			(82		)	(54		)	—			(54		)
Amortization of
prior service cost	—			97			97			—			99			99
unrecognized (gain) loss	10			(21		)	(11		)	—			(46		)	(46		)
Net periodic cost	$	10		$	425		$	435		$	29		$	383		$	412

In April 2012, Innophos contributed approximately $0.2 million to its U.S. defined benefit pension plan to satisfy the full year 2012 minimum contribution requirements.

Innophos made its entire cash contribution of $3.0 million for the U.S. defined contribution plan during the first quarter of 2012 for the plan year 2011.

Page 16 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Net periodic benefit expense for the Canadian plans:

	For the three months ended September 30, 2012								For the three months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	85		$	21	$	106		$	69		$	17		$	86
Interest cost	151			26		177			142			23			165
Expected return on assets	(236		)	—		(236		)	(238		)	—			(238		)
Amortization of
actuarial loss (gain)	65			11		76			—			7			7
prior service cost	26			—		26			26			—			26
net transition obligation	—			7		7			40			10			50
Exchange rate changes	122			22		144			(46		)	(10		)	(56		)
Net periodic cost	$	213		$	87	$	300		$	(7	)	$	47		$	40
	For the nine months ended September 30, 2012								For the nine months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	253		$	61	$	314		$	211		$	51		$	262
Interest cost	451			74		525			433			71			504
Expected return on assets	(706		)	—		(706		)	(726		)	—			(726		)
Amortization of
actuarial loss (gain)	195			35		230			—			23			23
prior service cost	78			—		78			80			—			80
net transition obligation	—			23		23			124			30			154
Exchange rate changes	142			29		171			140			(35		)	105
Net periodic cost	$	413		$	222	$	635		$	262		$	140		$	402

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.6 million during the nine months ended September 30, 2012. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.2 million during the remainder of 2012.

14. Segment Reporting

The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.

The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron and AMT are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.

Page 17 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the three months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	144,664	$	41,222	$	25,302		$	—		$	211,188
Intersegment sales	370		14,087		57			(14,514		)	—
Total sales	$	145,034	$	55,309	$	25,359		$	(14,514	)	$	211,188
Operating income (b)	$	22,759	$	2,369	$	(542	)	$	—		$	24,586
Depreciation and amortization expense	$	5,732	$	3,670	$	1,160		$	—		$	10,562
For the three months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	130,850	$	48,601	$	22,651		$	—		$	202,102
Intersegment sales	284		14,841		132			(15,257		)	—
Total sales	$	131,134	$	63,442	$	22,783		$	(15,257	)	$	202,102
Operating income (c)	$	21,331	$	7,143	$	4,651		$	—		$	33,125
Depreciation and amortization expense	$	4,864	$	4,909	$	1,753		$	—		$	11,526
For the nine months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	432,528	$	139,951	$	81,141		$	—		$	653,620
Intersegment sales	1,218		45,082		320			(46,620		)	—
Total sales	$	433,746	$	185,033	$	81,461		$	(46,620	)	$	653,620
Operating income (a) (b)	$	70,262	$	17,156	$	1,590		$	—		$	89,008
Depreciation and amortization expense	$	17,280	$	11,233	$	3,605		$	—		$	32,118
For the nine months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	393,262	$	132,634	$	75,431		$	—		$	601,327
Intersegment sales	1,056		35,522		312			(36,890		)	—
Total sales	$	394,318	$	168,156	$	75,743		$	(36,890	)	$	601,327
Operating income (c)	$	77,613	$	12,358	$	16,593		$	—		$	106,564
Depreciation and amortization expense	$	14,897	$	12,814	$	4,732		$	—		$	32,443

(a) The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.

(b) The nine months ended September 30, 2012 includes $2.4 million of out of period cost in Mexico in GTSP & Other.

(c) The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

Page 18 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

15. Acquisitions

The Company has made two recent acquisitions in the bioactive mineral ingredients sector. Bioactive mineral ingredients are mineral based ingredients for food, beverage and dietary supplement end markets that are manufactured to be readily digestible. Historically, Innophos has enjoyed a strong position in “macronutrients,” minerals such as calcium, magnesium and potassium that are required in relatively large amounts for a balanced diet. The human diet also requires smaller quantities of a wide range of other minerals such as chromium, selenium, zinc and iron classified as “micronutrients.” The acquisitions described below have created a strong position for Innophos in micronutrient bioactive mineral ingredients to complement the Company's existing strength in macronutrients.

In October 2011, Innophos acquired privately held Kelatron Corporation in a transaction accounted for under the acquisition method of accounting for business combinations. Kelatron, based in Ogden, Utah, is a leading producer of bioactive mineral nutrients sold into the nutritional and dietary supplements markets. The acquisition had a purchase price of approximately $21 million in cash, subject to working capital adjustments, and was funded from our revolving line of credit. Under the acquisition method of accounting, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date. The reported consolidated financial condition and results of operations after completion of the acquisition reflect those fair values, and Kelatron's results of operations have been included in the consolidated financial statements from the date of acquisition. The purchase accounting for the acquisition has been closed and immaterial adjustments were recognized in the second quarter of 2012.

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. The combined purchase price was $27.0 million in cash, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity, plus a contingent payment arrangement.The arrangement provides for payments of up to $3.0 million if certain new market development opportunities, measured by adjusted revenue, are realized following the acquisition. The fair value of the contingent consideration arrangement has been preliminarily set at $1.0 million based on probability of achievement and recorded at net present value, making for a total purchase price of $28.0 million. The cash was funded from our revolving line of credit, as well as cash from operations.

During the three months ended September 30, 2012, the Company's consolidated results of operations included revenues of $2.2 million with an immaterial effect on net income attributable to AMT.

The preliminary AMT purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below (in thousands):

Cash	$	325
Accounts receivable	841
Inventory, including step up of $352	2,020
Other current assets	39
Property, plant and equipment	9,483
Goodwill	6,494
Intangible assets	9,830
Accounts payable	(377		)
Other current liabilities	(1,237		)
Total	$	27,418

The intangible assets acquired in the AMT purchase include the following (in thousands):

Page 19 of 34

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

	Useful life (years)
Customer relationships	10-15	$	6,820
Developed technology	7	1,900
Tradename	5	930
Non-compete agreement	10	180
		$	9,830

The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition and will be included in the Specialty Phosphates US segment. The Company expects the goodwill created to be deductible for tax purposes. This transaction was treated as an asset purchase for U.S. federal tax purposes.

The customer relationships were valued based on the excess earnings method under the income approach which provides an estimate of the fair value based on a market participant. The after tax cash flows were discounted to present value using a 15.5% and 16.5% discount rate for direct customers and distributors, respectively.

Pro forma financial information (unaudited):

The following unaudited pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 and September 30, 2011 as if the acquisitions of Kelatron and AMT had been completed on January 1, 2011. The unaudited pro forma results do not reflect any material adjustments, operating efficiencies or potential cost savings which may result from the consolidation of operations.

	Three months ended				Nine months ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Revenues	$	211,382	$	208,117	$	660,380	$	622,214
Net income	$	16,902	$	18,199	$	60,500	$	66,070
Income per common share - Basic	$	0.78	$	0.84	$	2.77	$	3.04
Income per common share - Diluted	$	0.75	$	0.81	$	2.69	$	2.92

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion contains forward-looking statements about our markets, the demand for our products and services and our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially from those suggested by our forward-looking statements for various reasons including those discussed in the “Risk Factors” and “Forward-Looking Statements” sections of this report.

Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other mineral ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste and provide a wide range of mineral fortification solutions for food, beverage and nutritional supplement manufacturers.

Page 20 of 34

Recent Trends and Outlook

Market conditions for Specialty Phosphates are expected to continue at a similar level through the 2012 fourth quarter with demand expected to be similar or marginally below year ago levels. Management expects the US/Canada Specialty Phosphates business to continue achieving moderate organic year over year volume growth despite challenging external conditions, although on a sequential basis, volumes in the fourth quarter are typically 1-2% lower than the third quarter. Mexico Specialty Phosphates is expected to complete its subsequent planned maintenance outage activities during the fourth quarter according to schedule. Although the business is expected to restore fourth quarter volumes to the prior run rate, the ongoing maintenance program will limit the ability of the business to fully compensate for the shortfall in the third quarter.

Specialty Phosphates selling prices were 5% higher in the 2012 third quarter versus the same period last year, and the business is targeting further selling price increases in response to ongoing high levels for market raw material prices with a modest sequential benefit anticipated for the fourth quarter.

Maintenance spending, primarily for scheduled outages in the US and Mexico, along with exploration activities to support the evaluation of our mining concessions in Mexico, were in line with the $2 million expected, but more weighted towards maintenance. A similar level of expense is expected for the fourth quarter in these areas. Overall, therefore, management expects Specialty Phosphates operating performance in the 2012 fourth quarter to be broadly similar to the third quarter as improved Mexico Specialty Phosphate performance offsets the typical US/Canada seasonal volume decline. GTSP & Other operating performance is also expected to continue at approximately a break-even level through the fourth quarter.

Net debt (total debt less cash) increased by $17 million in the 2012 third quarter to $80 million resulting primarily from the $27 million acquisition of AMT and $7 million for the Company's previously announced stock repurchase program.

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. AMT specializes in mineral ingredients essential to the human diet that are manufactured in chelates and other forms so as to be easily digested (bioactive).

Capital Expenditures

Capital expenditures were $6 million in the 2012 third quarter and management now expects to spend approximately $25 million for all of 2012. As previously reported, the reduced expectation for capital expenditures is attributable to delays in some projects stemming from changes in engineering specifications. Investment continues to be focused on capacity enhancements for US / Canada and Mexico Specialty Ingredients facilities, expanding geographically, including the investment in China, and enhancing Mexico's capability to process multiple grades of phosphate rock, consistent with the Company's supply chain diversification strategy.

Hurricane Sandy

No manufacturing or distribution centers were affected directly by Hurricane Sandy. Although the company's R&D and corporate headquarters in Cranbury, NJ were without power for the work week since the storm passed on October 29, 2012 the facility was back to full service on November 5th. The Company does not expect the storm's effect on fourth quarter earnings to be material, but, at this time, it is unable to fully assess the impact of Hurricane Sandy on customer demand.

Page 21 of 34

Historical Performance

Results of Operations

The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated. (dollars in millions):

	Three Months Ended					Three Months Ended
	September 30, 2012					September 30, 2011
	Amount			%		Amount		%
Net sales	$	211.2		100.0		$	202.1	100.0
Cost of goods sold	168.4			79.7		152.9		75.7
Gross profit	42.8			20.3		49.2		24.3
Operating expenses:
Selling, general and administrative	17.5			8.3		15.3		7.6
Research & development	0.7			0.3		0.8		0.4
Income from operations	24.6			11.6		33.1		16.4
Interest expense, net	1.3			0.6		1.5		0.7
Foreign exchange losses (gains), net	(1.8		)	(0.9	)	1.4		0.7
Provision for income taxes	8.4			4.0		11.3		5.6
Net income	$	16.7		7.9		$	18.9	9.4

	Nine Months Ended					Nine Months Ended
	September 30, 2012					September 30, 2011
	Amount			%		Amount		%
Net sales	$	653.6		100.0		$	601.3	100.0
Cost of goods sold	512.6			78.4		445.6		74.1
Gross profit	141.0			21.6		155.7		25.9
Operating expenses:
Selling, general and administrative	49.7			7.6		46.9		7.8
Research & development	2.3			0.4		2.2		0.4
Income from operations	89.0			13.6		106.6		17.7
Interest expense, net	4.5			0.7		4.1		0.7
Foreign exchange losses (gains), net	(2.2		)	(0.3	)	2.0		0.3
Provision for income taxes	25.9			4.0		34.9		5.8
Net income	$	60.8		9.3		$	65.6	10.9

Three months ended September 30, 2012 compared to the three months ended September 30, 2011

Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended September 30, 2012 were $211.2 million, an increase of $9.1 million, or 4.5%, as compared to $202.1 million for the same period in 2011. Selling price increases had a positive effect on revenue of 2.3% or $4.6 million which included a 4.6% increase in Specialty Phosphates that was partially offset by lower pricing in GTSP & Other caused by fertilizer market prices that remained well below 2011 levels. Volumes increased 2.2% or $4.5 million on US/Canada Specialty Phosphates growth and higher GTSP & Other which in total were mostly offset by lower Mexico Specialty Phosphate volumes that were affected by a number of factors specific to the quarter, including weather related disruption and operating inefficiencies early in the quarter followed by scheduled maintenance outages which began later in the quarter.

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to

Page 22 of 34

date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

The following table illustrates for the three months ended September 30, 2012 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

	Price		Volume/Mix		Total
Specialty Phosphates US & Canada	3.9	%	6.7	%	10.6	%
Specialty Phosphates Mexico	6.5	%	(21.7	)%	(15.2	)%
Total Specialty Phosphates	4.6	%	(1.0	)%	3.6	%
GTSP & Other	(16.4	)%	28.1	%	11.7	%
Total	2.3	%	2.2	%	4.5	%

Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 4.4% and 3.3%, respectively, from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

The following table illustrates for the three months ended September 30, 2012 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:

	Price		Volume/Mix		Total
Specialty Ingredients	4.6	%	0.2	%	4.8	%
Food & Technical Grade PPA	11.5	%	0.5	%	12.0	%
STPP & Detergent Grade PPA	(4.4	)%	(9.5	)%	(13.9	)%

Note: Included within Specialty Ingredients volume/mix variance was a 4.7% benefit from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

Gross Profit

Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended September 30, 2012 was $42.8 million, a decrease of $6.4 million, or 13.0%, as compared to $49.2 million for the same period in 2011. Gross profit percentage decreased to 20.3% for the three months ended September 30, 2012 versus 24.3% for the same period in 2011. Gross profit was unfavorably affected by higher raw material costs, increased manufacturing cost which was partially offset by increased sales volume which had a combined unfavorable impact of $11.1 million. There was $1.1 million of increased expense for planned maintenance outages at our Geismar and Coatzacoalcos manufacturing facilities and $0.6 million for acquisition related fair value adjustments. Gross profit was favorably affected $4.6 million for higher selling prices, $0.7 million for lower depreciation, and $0.8 million of favorable exchange rate mostly from Mexican peso based costs. Included in 2011 was a charge of $0.3 million for the Mexican CNA matter.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended September 30, 2012 were $18.2 million, an increase of $2.1 million, or 13.0%, as compared to $16.1 million for the same period in 2011. The increase was primarily due to $1.0 million of expense in the newly acquired Kelatron and AMT businesses and $0.8 million of acquisition related expenses.

Operating Income

Operating income for the three months ended September 30, 2012 was $24.6 million, a decrease of $8.5 million, or 25.7%, as compared to $33.1 million for the same period in 2011. Operating income as a percentage of net sales decreased to 11.6% versus 16.4% for the same period in 2011, for the reasons noted above.

Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the three months ended September 30, 2012 was $1.3 million, a decrease of $0.2 million, or 13.3% as compared to $1.5 million for the same period in 2011.

Page 23 of 34

Foreign Exchange

Foreign exchange for the three months ended September 30, 2012 was a gain of $1.8 million as compared to a loss of $1.4 million for the same period in 2011. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

Provision for Income Taxes

The effective income tax rate was 33% for the three months ended September 30, 2012 compared to 37% for the same period in 2011. The variance in the effective tax rate is due to increased earnings in lower tax jurisdictions.

Net Income

Net income for the three months ended September 30, 2012 was $16.7 million, a decrease of $2.2 million as compared to $18.9 million for the same period in 2011, due to the factors described above.

Nine months ended September 30, 2012 compared to the nine months ended September 30, 2011

Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the nine months ended September 30, 2012 were $653.6 million, an increase of $52.3 million, or 8.7%, as compared to $601.3 million for the same period in 2011. Selling price increases had a positive effect on revenue of 4.8%, or $29.0 million, with Specialty Phosphates up 7.5% on positive trends in all product lines, partially offset by lower pricing in GTSP & Other with fertilizer market prices well below 2011 levels. Volumes increased 3.9% or $23.3 million with GTSP & Other contributing the most but also positive trends seen in the more specialized Purified Phosphoric Acid and Specialty Ingredients product lines.

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The following table illustrates for the nine months ended September 30, 2012 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

	Price		Volume/Mix		Total
Specialty Phosphates US & Canada	6.4	%	3.6	%	10.0	%
Specialty Phosphates Mexico	10.6	%	(5.1	)%	5.5	%
Total Specialty Phosphates	7.5	%	1.4	%	8.9	%
GTSP & Other	(13.7	)%	21.3	%	7.6	%
Total	4.8	%	3.9	%	8.7	%

Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 3.6% and 2.7%, respectively, from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

The following table illustrates for the nine months ended September 30, 2012 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:

	Price		Volume/Mix		Total
Specialty Ingredients	6.9	%	1.4	%	8.3	%
Food & Technical Grade PPA	10.9	%	6.8	%	17.7	%
STPP & Detergent Grade PPA	5.9	%	(6.7	)%	(0.8	)%

Note: Included within Specialty Ingredients volume/mix was a 3.9% benefit from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

Page 24 of 34

Gross Profit

Gross profit represents net sales less cost of goods sold. Gross profit for the nine months ended September 30, 2012 was $141.0 million, a decrease of $14.7 million, or 9.4%, as compared to $155.7 million for the same period in 2011. Gross profit percentage decreased to 21.6% for the nine months ended September 30, 2012 versus 25.9% for the same period in 2011. Gross profit was unfavorably affected by higher raw material costs partially offset by increased volumes which had a combined unfavorable impact of $52.0 million. There was a $0.5 million unfavorable impact for a planned maintenance outage at our Geismar facility offset by a net benefit of $2.6 million for scheduled maintenance outages at Coatzacoalcos. There was $2.4 million of out of period cost in Mexico during the nine months ended September 30, 2012, which was partially offset by revision to our estimates for the effect of contract terms on raw material pricing in 2012 of $1.2 million. Gross profit was favorably affected $29.0 million for higher selling prices, $7.1 million primarily due to the recording of a settlement with Rhodia on their liability for the charges to be paid to the Mexican water authority (CNA), $2.1 million favorable exchange rate impact mostly from Mexican peso based costs, and $2.4 million lower depreciation. Included in 2012 was $0.6 million for acquisition related fair value adjustments and in 2011 there was $3.6 million income for updates to the provision for the Mexican CNA Water Tax Claims.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the nine months ended September 30, 2012 were $52.0 million, an increase of $2.9 million, or 5.9%, as compared to $49.1 million for the same period in 2011. The increase was due to $2.1 million higher depreciation due to the ERP system that was put into service in the third quarter of 2011, $2.0 million increase for the Kelatron and AMT businesses and $0.8 million of acquisition related expenses, partially offset by $1.8 million lower non-cash stock compensation.

Operating Income

Operating income for the nine months ended September 30, 2012 was $89.0 million, a decrease of $17.6 million, or 16.5%, as compared to $106.6 million for the same period in 2011. Operating income as a percentage of net sales decreased to 13.6% versus 17.7% for the same period in 2011, for the reasons noted above.

Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the nine months ended September 30, 2012 was $4.5 million, an increase of $0.4 million, or 9.8% as compared to $4.1 million for the same period in 2011.

Foreign Exchange

Foreign exchange gain for the nine months ended September 30, 2012 was $2.2 million as compared to a loss of $2.0 million for the same period in 2011. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

Provision for Income Taxes

The effective income tax rate was 30% for the nine months ended September 30, 2012 compared to 35% for the same period in 2011. The variance in the effective tax rate is primarily due to the Rhodia settlement related to the Mexican CNA Water Tax Claims being recorded as a discrete item for income tax provision purposes in the first quarter of 2012 which had a 3% effect on the effective tax rate.

Net Income

Net income for the nine months ended September 30, 2012 was $60.8 million, a decrease of $4.8 million as compared to $65.6 million for the same period in 2011, due to the factors described above.

Page 25 of 34

Segment Reporting

The Company reports its core Specialty Phosphates business separately from GTSP & Other. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA and STPP & Detergent Grade PPA. Kelatron and AMT are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. GTSP & Other includes fertilizer co-product GTSP and other non-Specialty Phosphate products. The primary performance indicators for the chief operating decision maker are sales and operating income. The following table sets forth the historical results of these indicators by segment:

	Three Months Ended
	September 30, 2012			September 30, 2011			Net Sales % Change
Segment Net Sales
Specialty Phosphates US & Canada	$	144,664		$	130,850		10.6	%
Specialty Phosphates Mexico	41,222			48,601			(15.2	)%
Total Specialty Phosphates	185,886			179,451			3.6	%
GTSP & Other	25,302			22,651			11.7	%
Total	$	211,188		$	202,102		4.5	%
Segment Operating Income
Specialty Phosphates US & Canada	$	22,759		$	21,331
Specialty Phosphates Mexico	2,369			7,143
Total Specialty Phosphates	25,128			28,474
GTSP & Other (a)	(542		)	4,651
Total	$	24,586		$	33,125
Segment Operating Income % of net sales
Specialty Phosphates US & Canada	15.7		%	16.3		%
Specialty Phosphates Mexico	5.7		%	14.7		%
Total Specialty Phosphates	13.5		%	15.9		%
GTSP & Other (a)	(2.1		)%	20.5		%
Total	11.6		%	16.4		%
Depreciation and amortization expense
Specialty Phosphates US & Canada	$	5,732		$	4,864
Specialty Phosphates Mexico	3,670			4,909
Total Specialty Phosphates	$	9,402		9,773
GTSP & Other	1,160			1,753
Total	$	10,562		$	11,526

(a) The three months ended September 30, 2011 includes a $0.3 million charge to earnings related to updates to the provision for the CNA Fresh Water Claims.

Page 26 of 34

	Nine Months Ended
	September 30, 2012			September 30, 2011			Net Sales % Change
Segment Net Sales
Specialty Phosphates US & Canada	$	432,528		$	393,262		10.0	%
Specialty Phosphates Mexico	139,951			132,634			5.5	%
Total Specialty Phosphates	572,479			525,896			8.9	%
GTSP & Other	81,141			75,431			7.6	%
Total	$	653,620		$	601,327		8.7	%
Segment Operating Income
Specialty Phosphates US & Canada	$	70,262		$	77,613
Specialty Phosphates Mexico	17,156			12,358
Total Specialty Phosphates	87,418			89,971
GTSP & Other (a) (b)	1,590			16,593
Total	$	89,008		$	106,564
Segment Operating Income % of net sales
Specialty Phosphates US & Canada	16.2		%	19.7		%
Specialty Phosphates Mexico	12.3		%	9.3		%
Total Specialty Phosphates	15.3		%	17.1		%
GTSP & Other (a) (b)	2.0		%	22.0		%
Total	13.6		%	17.7		%
Depreciation and amortization expense
Specialty Phosphates US & Canada	$	17,280		$	14,897
Specialty Phosphates Mexico	11,233			12,814
Total Specialty Phosphates	$	28,513		27,711
GTSP & Other	3,605			4,732
Total	$	32,118		$	32,443

(a) The nine month period ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims and a $2.4 million charge to earnings for out of period costs in Mexico.

(b) The nine months ended September 30, 2011 includes a $3.6 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims.

Three months ended September 30, 2012 compared to the three months ended September 30, 2011

Segment Net Sales:

Specialty Phosphates US & Canada net sales increased 10.6% for the three months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 3.9% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes increased 6.7% with increases across all product lines including a benefit of 4.4% for the Kelatron and AMT acquisitions.

Specialty Phosphates Mexico net sales decreased 15.2% for the three months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 6.5% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes decreased 21.7% with decreases across all product lines that were affected by a number of factors specific to the quarter, including weather related disruption and operating inefficiencies early in the quarter followed by scheduled maintenance outages which began later in the quarter.

Page 27 of 34

GTSP & Other net sales increased 11.7% for the three months ended September 30, 2012 when compared with the same period in 2011 on 28.1% higher volumes. Selling prices decreased 16.4% with fertilizer market prices well below 2011 levels.

Segment Operating Income Percentage of Net Sales:

The 60 basis point decrease in Specialty Phosphates US & Canada for the three months ended September 30, 2012 compared with the same period in 2011 is mainly due to increased raw material costs, expense for a maintenance outage in the current period, depreciation and acquisition related fair value adjustments which combined for a 370 basis point decrease in margin percent. This was partially offset by increased selling prices which increased margins by 310 basis points.

The 900 basis point decrease in Specialty Phosphates Mexico for the three months ended September 30, 2012 compared with the same period in 2011 is mainly due to lower volumes, higher raw material costs which exceeded lower operating expenses and depreciation contributing a 1,430 basis point decrease in margins. This was partially offset by increased selling prices which increased margins by 530 basis points.

The 2,260 basis point decrease in GTSP & Other for the three months ended September 30, 2012 compared with the same period in 2011 is primarily due to lower selling prices which decreased margin by 1,550 basis points. Higher raw material costs exceeded lower manufacturing expenses and depreciation which decreased margins by 830 basis points. The charge included in 2011 for the Mexican CNA matter increases margin by 120 basis points.

Nine months ended September 30, 2012 compared to the nine months ended September 30, 2011

Segment Net Sales:

Specialty Phosphates US & Canada net sales increased 10.0% for the nine months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 6.4% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes increased 3.6% due to the benefit of the Kelatron and AMT acquisitions.

Specialty Phosphates Mexico net sales increased 5.5% for the nine months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 10.6% with increases across all product lines. Volumes decreased 5.1% primarily in STPP & Detergent Grade PPA.

GTSP & Other net sales increased 7.6% for the nine months ended September 30, 2012 when compared with the same period in 2011, with 21.3% higher volumes. This was partially offset by 13.7% lower selling prices caused by fertilizer market prices that were well below 2011 levels.

Segment Operating Income Percentage of Net Sales:

The 350 basis point decrease in Specialty Phosphates US & Canada for the nine months ended September 30, 2012 compared with the same period in 2011 is mainly due to increases in raw material costs, manufacturing expenses, depreciation, operating expenses, and a maintenance outage in the current year which combined for an 840 basis point decrease in margins. Partially offsetting was increased selling prices which increased margins by 490 basis points.

The 300 basis point increase in Specialty Phosphates Mexico for the nine months ended September 30, 2012 compared with the same period in 2011 is mainly due to increased selling prices which increased margins by 870 basis points. Higher raw material costs were partially offset by lower manufacturing expenses, operating expenses, depreciation, and the net benefit from the maintenance outages in both years combining for a 570 basis point decrease in margins.

The 2,000 basis point decrease in GTSP & Other for the nine months ended September 30, 2012 compared with the same period in 2011 is primarily due to lower selling prices which decreased margins by 1,230 basis points. Higher raw material costs which exceeded a benefit from the 2011 maintenance outage and lower depreciation contributed an 870 basis point decrease in margins. The net effect of the 2012 versus 2011 benefit of $3.5 million for the settlement with Rhodia on their liability for the charges to be paid to the CNA increased margins by 460 basis points. Out of period costs in the current period, net of revision to our estimates for the effect of contract terms on raw material pricing in 2012, decreased margins by 360 basis points.

Page 28 of 34

Liquidity and Capital Resources

The following table sets forth a summary of the Company’s cash flows for the periods indicated.

(Dollars in millions)	Nine months ended
	September 30, 2012			September 30, 2011
Operating Activities	$	100.8		$	75.4
Investing Activities	(43.1		)	(27.2		)
Financing Activities	(56.4		)	(25.7		)

Nine months ended September 30, 2012 compared to nine months ended September 30, 2011

Net cash provided by operating activities was $100.8 million for the nine months ended September 30, 2012 as compared to $75.4 million for 2011, an increase of $25.4 million. The increase in operating activities cash resulted primarily from favorable changes of $41.4 million in working capital partially offset by unfavorable changes of $10.5 million in non-cash adjustments to income, $0.7 million in other long term assets and liabilities and $4.8 million in net income as described earlier.

The change in working capital is a source of cash of $9.6 million in 2012 compared to a use in 2011 of $31.8 million, an increase in cash of $41.4 million, primarily the result of reduced accounts receivable and inventory levels in 2012 compared to increased levels in 2011, offset partially by higher creditable tax balances for our Mexico entities and by reduced levels of current liabilities. The higher creditable tax balances are due to required prepayments of income taxes and slowness of value added tax, or VAT refunds due to the Company from the Mexico government. The Company believes all VAT amounts due from the Mexico government are fully collectible.

Net cash used for investing activities was $43.1 million for the nine months ended September 30, 2012, compared to $27.2 million for 2011 an increase of $15.9 million. The change is mainly due to the $27.1 million investment in AMT made in the third quarter of 2012. This was partially offset by $11.2 million lower capital spending mainly on the company's ERP project and an expansion project at Nashville, TN.

Management projects total 2012 capital expenditures to be approximately $25 million.

Innophos currently estimates that full exploration costs to a proven reserves standard for its Baja California mining concessions could require expenditures of $10 to $15 million over a period, currently estimated at three to five years, inclusive of expenditures to date. This estimate includes mineral rights payments, taxes, mineral resource measurement, beneficiation process design and completion of feasibility studies. Full expenditures would only occur if interim milestone goals were successfully attained. Combined 2010 and 2011 expenditures on the exploration of the Baja California Sur concession deposits were approximately $2.4 million, and management currently expects to spend an additional $2-4 million in 2012-2013 above the previous trend rate to accelerate evaluations of its Santo Domingo concession. Innophos intends to seek one or more partners for these efforts, but anticipates no difficulties in completing the exploration phase without a partnership.

Net cash from financing activities for the nine months ended September 30, 2012, was a use of $56.4 million, compared to a use of $25.7 million in 2011, an increase in the use of cash of $30.7 million. This was mainly due to $27.0 million lower borrowings, $2.7 million higher dividend payments, and $1.1 million increased common stock repurchases.

Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.

On September 30, 2012, the Company had cash and cash equivalents outside the United States of $28.6 million, or 78% of the Company's balance. Further, the foreign cash amounts are not restricted by law to be used in other countries. Our current operating plan does not include repatriation of any of the cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United States taxes to repatriate these funds.

Page 29 of 34

The Company's available financial resources allow for the continuation of dividend payments, pursuit of several “bolt-on” acquisition projects and further geographic expansion initiatives. We further believe that on-hand cash combined with cash generated from operations, including our Mexican operations, and availability under our revolving line of credit, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash and our future operating cash flows. However, future operating performance for the Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating plans.

On February 27, 2012 the Company's Board of Directors declared an increase to its dividend from $0.25 per share to $0.27 per share to holders of record on April 16, 2012. On October 26, 2012 the Company's Board of Directors declared an increase to its dividend from $0.27 per share to $0.35 per share to holders of record on November 16, 2012.

On July 17, 2012, Innophos, Inc. purchased for cash 100% of the equity of AMT Labs, Inc. and an affiliated real estate company holding all AMT real property, including unused land and buildings to support future expansion. The combined purchase price was $27 million, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity. The transaction includes potential for additional consideration of up to $3 million contingent upon success in developing new market opportunities. The price was funded from our revolving line of credit as well as cash from operations.

Critical Accounting Estimates and Policies

There have been no material changes from the critical accounting estimates previously disclosed in our 2011 Annual Report on Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our Loan Agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.

At September 30, 2012, we had $92.0 million principal amount of variable-rate debt and a $125.0 million revolving credit facility, of which $25.0 million was outstanding, both of which approximate fair value, determined using level 2 inputs within the fair value hierarchy. Total remaining availability was $98.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. In the third quarter of 2010 we entered into an interest rate swap with an original notional amount of $100 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 1.994% plus the applicable margin on the debt, expiring in August 2015. The Company exercised its right to cancel the swap with no fee on September 28, 2012.

Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our cash flow has been used to service debt and fund working capital needs, which may affect our ability to make future acquisitions or capital expenditures. We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $117.0 million outstanding borrowings as floating rate debt under our revolving credit facility, an immediate increase of one percentage point would cause an increase to interest expense of approximately $1.2 million per year.

From time to time, we may enter into longer term natural gas supply contracts in an effort to eliminate some of the volatility in our energy costs. Our natural gas spending for 2012 is estimated to be less than 2% of cost of goods sold. We did enter into a financial hedge for approximately 75% of our 2012 U.S. & Canada natural gas requirements, to reduce price volatility using fixed price contracts. At September 30, 2012, there was approximately zero fair value for these natural gas contracts.

We do not currently hedge our currency rate risks.

Page 30 of 34

We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.

Foreign Currency Exchange Rates

The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are translated at current exchange rates, non-monetary assets and liabilities are translated at historical exchange rates, and revenue and expenses are translated at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.

Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal.

Inflation and changing prices

Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers could have a material effect on our financial condition and results of operations.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Control and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

As of September 30, 2012 the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during or with respect to the third quarter of 2012 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Page 31 of 34

PART II

ITEM 1. LEGAL PROCEEDINGS

Note 12 of Notes to Consolidated Condensed Financial Statements in “Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in our 2011 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

a) Exhibits. The following exhibits are filed or furnished as part of this report:

Exhibit No.	Description
31.1	Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.

Page 32 of 34

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INNOPHOS HOLDINGS, INC.
	/s/ Randolph Gress
By:	Randolph Gress
Its:	Chief Executive Officer and Director
	(Principal Executive Officer)
Dated:	November 8, 2012
INNOPHOS HOLDINGS, INC.
	/s/ Neil I. Salmon
By:	Neil I. Salmon
Its:	Vice President and Chief Financial Officer
	(Principal Financial Officer)
Dated:	November 8, 2012

Page 33 of 34

EXHIBIT INDEX

Exhibit No.	Description
31.1	Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Page 34 of 34

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Randolph Gress, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 8, 2012	By:	/S/    RANDOLPH GRESS
		Randolph Gress
		Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2

Exhibit 31.2

I, Neil I. Salmon, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 8, 2012	By:	/S/    NEIL I. SALMON
		Neil I. Salmon
		Vice President and Chief Financial Officer (Principal Financial Officer)

EX-32.1

Exhibit 32.1

Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)

I, Randolph Gress, certify that:

1. the accompanying Quarterly Report on Form 10-Q for the period ended September 30, 2012 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.

A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.

Date: November 8, 2012

/S/    RANDOLPH GRESS        

Randolph Gress

Chief Executive Officer and Director

(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.

EX-32.2

Exhibit 32.2

Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)

I, Neil I. Salmon, certify that:

1. the accompanying Quarterly Report on Form 10-Q for the period ended September 30, 2012 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.

A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.

Date: November 8, 2012

/S/    NEIL I. SALMON        

Neil I. Salmon

Vice President and Chief Financial Officer

(Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.

XML

Dividends (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			9 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Dividends [Abstract]
Dividends declared - per share	$ 0.35	$ 0.00	$ 0.25	$ 0.54	$ 0.75
Dividends declared - aggregate		$ 0	$ 5,442	$ 11,776	$ 16,309
Dividends paid - per share		$ 0.27	$ 0.25	$ 0.79	$ 0.67
Dividends paid - aggregate		$ 5,891	$ 5,442	$ 17,181	$ 14,517

XML

Acquisitions Schedule of Purchase Price Allocation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jul. 17, 2012
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	$ 211,382,000	$ 208,117,000	$ 660,380,000	$ 622,214,000
Inventory					352,000
Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Amount					9,830,000
Business Acquisition, Pro Forma Net Income (Loss)	16,902,000	18,199,000	60,500,000	66,070,000
Business Acquisition, Pro Forma Earnings Per Share, Basic	$ 0.78	$ 0.84	$ 2.77	$ 3.04
Business Acquisition, Pro Forma Earnings Per Share, Diluted	$ 0.75	$ 0.81	$ 2.69	$ 2.92
AMT [Member]
Business Acquisition [Line Items]
Cash					325,000
Accounts receivable					841,000
Inventory					2,020,000
Other current assets					39,000
Property, plant and equipment					9,483,000
Goodwill					6,494,000
Intangible assets					9,830,000
Accounts payable					(377,000)
Other current liabilities					(1,237,000)
Finite-Lived Intangible Assets [Abstract]
Business Acquisition, Purchase Price Allocation, Current Liabilities					27,418,000
Customer Relationships [Member] | AMT [Member]
Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Amount					6,820,000
Developed Technology Rights [Member] | AMT [Member]
Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Amount					1,900,000
Trade Names [Member] | AMT [Member]
Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Amount					930,000
Noncompete Agreements [Member] | AMT [Member]
Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Amount					$ 180,000

XML

Other Long-Term Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Deferred income taxes	$ 23,761	$ 24,308
Pension and post retirement liabilities (U.S. and Canada only)	6,290	6,185
Environmental liabilities	1,100	1,100
Profit sharing and post employment liabilities	4,478	3,795
Other liabilities	1,237	2,170
Other Liabilities, Noncurrent	$ 36,866	$ 37,558

XML

Acquisitions Business Acquisition, Pro Forma Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jul. 17, 2012 AMT Labs Real Estate [Member]	Jul. 17, 2012 AMT Labs [Member]	Oct. 31, 2011 Kelatron Corporation [Member]
Business Acquisition [Line Items]
Business Acquisition, Purchase Price Allocation, Property					$ 7,500,000
Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net						19,500,000
Business Acquisition, Cost of Acquired Entity, Purchase Price							21,000,000
Revenues	211,382,000	208,117,000	660,380,000	622,214,000
Net income	$ 16,902,000	$ 18,199,000	$ 60,500,000	$ 66,070,000
Income per common share - Basic	$ 0.78	$ 0.84	$ 2.77	$ 3.04
Income per common share - Diluted	$ 0.75	$ 0.81	$ 2.69	$ 2.92

XML

Other Current Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Other Liabilities, Current [Abstract]
CNA water tax claims	$ 10,592	$ 31,523
Payroll related	10,820	11,708
Taxes	9,292	5,885
Benefits and pensions	5,884	7,717
Freight and rebates	4,962	4,418
Dividends payable	0	5,405
Other	6,958	4,953
Other Liabilities, Current	$ 48,508	$ 71,609

XML

Other Long-Term Liabilities (Tables)

9 Months Ended

Sep. 30, 2012

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Schedule of Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	September 30, 2012		December 31, 2011
Deferred income taxes	$	23,761	$	24,308
Pension and post retirement liabilities (U.S. and Canada only)	6,290		6,185
Environmental liabilities	1,100		1,100
Profit sharing and post employment liabilities	4,478		3,795
Other liabilities	1,237		2,170
	$	36,866	$	37,558

XML

Earnings Per Share (EPS) Earnings Per Share (EPS) (Tables)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended					Nine Months Ended
	September 30, 2012			September 30, 2011		September 30, 2012			September 30, 2011
Net income	$	16,706		$	18,857	$	60,798		$	65,572
Less: earnings attributable to unvested shares	(11		)	—		(40		)	—
Net income available to common shareholders	$	16,695		$	18,857	$	60,758		$	65,572
Weighted average number of common and potential common shares outstanding:
Basic number of common shares outstanding	21,807,013			21,691,892		21,804,415			21,719,580
Dilutive effect of stock equivalents	693,249			865,769		714,945			885,265
Diluted number of weighted average common shares outstanding	22,500,262			22,557,661		22,519,360			22,604,845
Earnings per common share:
Earnings per common share—Basic	$	0.77		$	0.87	$	2.79		$	3.02
Earnings per common share—Diluted	$	0.74		$	0.84	$	2.70		$	2.90
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	387,878			422,734		366,182			403,238

XML

Commitments and Contingencies (Details) (USD $)	9 Months Ended				3 Months Ended	1 Months Ended		12 Months Ended	3 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012 Environmental [Member]	Sep. 30, 2012 RCRA Civil Enforcement, Geismar Plant [Member]	Sep. 30, 2012 Mexican Comision National Water Tax Claims, Post-2002 [Member]	Oct. 31, 2009 Mexicana vs. Sudamfos Lawsuit [Member]	Oct. 31, 2008 Mexicana vs. Sudamfos Lawsuit [Member]	Dec. 31, 2008 Mexicana vs. Sudamfos Lawsuit [Member] Mg	Sep. 30, 2012 Minimum [Member] Environmental [Member]	Sep. 30, 2012 Maximum [Member] Environmental [Member]
Loss Contingencies [Line Items]
Environmental Exit Costs, Anticipated Cost									$ 0.9	$ 1,200,000
Accrual for Environmental Loss Contingencies	1,100,000	1,100,000	1,100,000
Document Period End Date	Sep. 30, 2012
Loss Contingency, Range of Possible Loss, Minimum				10,000,000
Loss Contingency, Range of Possible Loss, Maximum				16,000,000
Loss Contingency, Damages Sought, Value					10,600,000		1,200,000
Phosphoric Acid								12,500
Loss Contingency, Damages Sought, Counter Lawsuit						$ 3,000,000

XML

Share-Based Compensation - Summary of Assumptions Used in the Option-Pricing Model (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Share-based Compensation [Abstract]
Expected volatility		53.20%
Dividend yield		2.40%
Risk-free interest rate		1.30%
Expected term		6 years
Weighted average grant date fair value of stock options		$ 20.41
Share-based Compensation Arrangement by Share-based Payament Award, Fair Value Assumptions, Historical Average Volatility Rate of Peer Group	50.00%
Share-based Compensation Arrangement by Share-based Payament Award, Fair Value Assumptions, Historical Average Volatility Rate	50.00%

XML

Basis of Statement Presentation Basis of Statement Presentation (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount		$ 2.4
Cost of Goods, Total [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount	3.9	2.4
Net Income [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount	$ 2.6	$ 1.6

XML

Segment Reporting (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Mar. 31, 2011	Sep. 30, 2012		Sep. 30, 2011		Dec. 31, 2011
Segment Reporting Information [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount				$ 2,400,000
Sales	211,188,000	202,102,000		653,620,000		601,327,000
Intersegment sales	0	0		0		0
Total sales	211,188,000	202,102,000		653,620,000		601,327,000
Operating income	24,586,000	33,125,000		89,008,000	[1]	106,564,000	[2]
Depreciation and amortization expense	10,562,000	11,526,000		32,118,000		32,443,000
Long-lived assets	185,876,000			185,876,000				187,421,000
Assets	677,280,000			677,280,000				687,015,000
Gain (Loss) Related to Litigation Settlement				7,100,000		3,600,000
Litigation Settlement, Expense			300,000
Specialty Phosphates US & Canada [Member]
Segment Reporting Information [Line Items]
Sales	144,664,000	130,850,000		432,528,000		393,262,000
Intersegment sales	370,000	284,000		1,218,000		1,056,000
Total sales	145,034,000	131,134,000		433,746,000		394,318,000
Operating income	22,759,000	21,331,000		70,262,000	[1]	77,613,000	[2]
Depreciation and amortization expense	5,732,000	4,864,000		17,280,000		14,897,000
Specialty Phosphates Mexico [Member]
Segment Reporting Information [Line Items]
Sales	41,222,000	48,601,000		139,951,000		132,634,000
Intersegment sales	14,087,000	14,841,000		45,082,000		35,522,000
Total sales	55,309,000	63,442,000		185,033,000		168,156,000
Operating income	2,369,000	7,143,000		17,156,000	[1]	12,358,000	[2]
Depreciation and amortization expense	3,670,000	4,909,000		11,233,000		12,814,000
GTSP & Other [Member]
Segment Reporting Information [Line Items]
Sales	25,302,000	22,651,000		81,141,000		75,431,000
Intersegment sales	57,000	132,000		320,000		312,000
Total sales	25,359,000	22,783,000		81,461,000		75,743,000
Operating income	(542,000)	4,651,000		1,590,000	[1]	16,593,000	[2]
Depreciation and amortization expense	1,160,000	1,753,000		3,605,000		4,732,000
Eliminations [Member]
Segment Reporting Information [Line Items]
Sales	0	0		0		0
Intersegment sales	(14,514,000)	(15,257,000)		(46,620,000)		(36,890,000)
Total sales	(14,514,000)	(15,257,000)		(46,620,000)		(36,890,000)
Operating income	0	0		0	[1]	0	[2]
Depreciation and amortization expense	$ 0	$ 0		$ 0		$ 0

[1] The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.

[2] The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Debt and Interest (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Mar. 31, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2010	Aug. 27, 2010
Debt Instrument [Line Items]
Term loan due 2015	$ 92,000,000			$ 92,000,000		$ 95,000,000
Revolver borrowings under the credit facility	25,000,000			25,000,000		57,000,000
Short-Term and Long-Term Debt Total, Gross	117,000,000			117,000,000		152,000,000
Current portion of long-term debt	4,000,000			4,000,000		4,000,000
Long-term debt	113,000,000			113,000,000		148,000,000
Repayments of Debt, Percent of Original Loan Balance								1.00%
Line of Credit Facility, Remaining Borrowing Capacity	98,100,000			98,100,000
Debt, Weighted Average Interest Rate	4.10%			4.10%
Amortization of Financing Costs	141,000		149,000	428,000	461,000
Notional Amount of Interest Rate Derivatives							100,000,000
Interest Paid				4,355,000	4,504,000
Interest Expense [Abstract]
Interest expense	1,371,000		1,478,000	4,350,000	4,475,000
Deferred financing cost	141,000		149,000	428,000	461,000
Interest income	(11,000)		(98,000)	(55,000)	(403,000)
Less: amount capitalized for capital projects	(187,000)		(27,000)	(187,000)	(446,000)
Total interest expense, net	1,314,000	1,502,000	1,502,000	4,536,000	4,087,000
Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity								125,000,000
Letter of Credit, Sub-Facility [Member]
Debt Instrument [Line Items]
Revolver borrowings under the credit facility	1,900,000			1,900,000
Line of Credit Facility, Current Borrowing Capacity								20,000,000
Term Loan [Member]
Debt Instrument [Line Items]
Term loan due 2015	$ 92,000,000			$ 92,000,000				100,000,000
Debt Instrument, Interest Rate, Stated Percentage								1.994%

XML

Basis of Statement Presentation

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2011 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2011 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

Out of Period Adjustments

During the second quarter of fiscal 2012, we identified certain adjustments in our financial statements related to 2011 through the first quarter of fiscal 2012. We corrected the items during the second quarter of fiscal 2012, which had the effect of increasing cost of goods sold by $3.9 million, and decreasing net income by $2.6 million. The impact of these items for the nine months ended September 30, 2012 increased cost of goods sold by $2.4 million and decreased net income by $1.6 million. These prior period adjustments are not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. These adjustments are also not expected to be material to the full year 2012 financial statements.

Recently Issued Accounting Standards

Adopted

In May 2011, the FASB issued changes to conform existing guidance regarding fair value measurement and disclosure between U.S. GAAP and International Financial Reporting Standards. These changes both clarify the FASB's intent about the application of existing fair value measurement and disclosure requirements and amend certain principles or requirements for measuring fair value or for disclosing information about fair value measurements. The clarifying changes relate to the application of the highest and best use and valuation premise concepts, measuring the fair value of an instrument classified in a reporting entity's shareholders' equity, and disclosure of quantitative information about unobservable inputs used for Level 3 fair value measurements. The amendments relate to measuring the fair value of financial instruments that are managed within a portfolio; application of premiums and discounts in a fair value measurement; and additional disclosures concerning the valuation processes used and sensitivity of the fair value measurement to changes in unobservable inputs for those items categorized as Level 3, a reporting entity's use of a nonfinancial asset in a way that differs from the asset's highest and best use, and the categorization by level in the fair value hierarchy for items required to be measured at fair value for disclosure purposes only. These changes become effective for the Company on January 1, 2012. The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.

In September 2011, the FASB issued amendments to the goodwill impairment guidance which provides an option for companies to use a qualitative approach to test goodwill for impairment if certain conditions are met. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 (early adoption is permitted). The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.

Issued but not yet adopted

In July 2012, the Financial Accounting Standards Board issued updated guidance on the periodic testing of indefinite-lived intangible assets for impairment. The updated guidance gives companies the option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount and, thus, whether further impairment testing is necessary. The updated accounting guidance is effective for fiscal years beginning after September 15, 2012, with early adoption permitted. The implementation of this standard will not have a material impact on the Company's consolidated financial position and results of operations.

XML

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Inventory Disclosure [Abstract]
Raw materials	$ 39,454	$ 44,937
Finished goods	105,878	116,488
Spare parts	8,908	8,303
Inventory, Net	154,240	169,728
Inventory Valuation Reserves	$ 11,849	$ 9,911

XML

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2012

Other Current Assets: [Abstract]

Schedule of Other Assets [Table Text Block]

Other current assets consist of the following:

	September 30, 2012		December 31, 2011
Rhodia indemnity receivable for CNA water tax claims (see note 12)	$	—	$	13,571
Creditable taxes (value added taxes)	31,957		20,473
Vendor inventory deposits (prepaid)	12,036		19,671
Prepaid income taxes	17,324		4,829
Other prepaids	2,397		2,585
Deferred income taxes	10,348		10,347
Other	4,431		3,840
	$	78,493	$	75,316

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2012

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following:

	September 30, 2012		December 31, 2011
Raw materials	$	39,454	$	44,937
Finished products	105,878		116,488
Spare parts	8,908		8,303
	$	154,240	$	169,728

XML

Other Current Assets (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Other Current Assets: [Abstract]
Rhodia indemnity receivable for CNA water tax claims	$ 0	$ 13,571
Creditable taxes (value added taxes)	31,957	20,473
Vendor inventory deposits (prepaid)	12,036	19,671
Prepaid income taxes	17,324	4,829
Other prepaids	2,397	2,585
Deferred income taxes	10,348	10,347
Other	4,431	3,840
Other Assets, Current	$ 78,493	$ 75,316

XML

Intangibles and Other Assets, net Intangibles and Other Assets, net (Tables)

9 Months Ended

Sep. 30, 2012

Intangibles and Other Assets, net: [Abstract]

Intangibles and Other Assets [Table Text Block]

Intangibles and other assets consist of the following:

	Useful life (years)	September 30, 2012		December 31, 2011
Developed technology and application patents, net of accumulated amortization of $15,585 for 2012 and $13,980 for 2011	7-20	$	24,305	$	24,010
Customer relationships, net of accumulated amortization of $7,203 for 2012 and $5,956 for 2011	5-15	18,907		13,333
Tradenames and license agreements, net of accumulated amortization of $4,676 for 2012 and $4,246 for 2011	5-20	6,474		5,974
Non-compete agreements, net of accumulated amortization of $636 for 2012 and $568 for 2011	5-10	184		73
Total intangibles		$	49,870	$	43,390
Deferred financing costs, net of accumulated amortization of $1,265 for 2012 and $837 for 2011 (see note 9)		$	1,563	$	1,991
Deferred income taxes		5,768		5,450
Other Assets		2,868		2,469
Total other assets		$	10,199	$	9,910
		$	60,069	$	53,300

XML

Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2012

Other Liabilities, Current [Abstract]

Other Current Liabilities [Table Text Block]

Other current liabilities consist of the following:

	September 30, 2012		December 31, 2011
CNA water tax claims (see Note 12)	$	10,592	$	31,523
Payroll related	10,820		11,708
Taxes	9,292		5,885
Benefits and pensions	5,884		7,717
Freight and rebates	4,962		4,418
Dividends payable	—		5,405
Other	6,958		4,953
	$	48,508	$	71,609

XML

Statements of Stockholders' Equity (Unaudited) Statements of Stockholders' Equity Parenthetical (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Other Comprehensive Income (Loss), Tax	$ 382,000	$ 836,000

XML

Debt and Interest (Tables)

9 Months Ended

Sep. 30, 2012

Short-term Borrowings, Long-Term Debt, and Interest Expense: [Abstract]

Short-Term Borrowings and Long-Term Debt [Table Text Block]

Short-term borrowings and long-term debt consist of the following:

	September 30, 2012		December 31, 2011
Term loan due 2015	$	92,000	$	95,000
Revolver borrowings under the credit facility	25,000		57,000
Total borrowings	$	117,000	$	152,000
Less current portion	4,000		4,000
Long-term debt	$	113,000	$	148,000

Components of Interest Expense, Net [Table Text Block]

Interest expense, net consists of the following:

	Three months ended						Nine months ended
	September 30, 2012			September 30, 2011			September 30, 2012			September 30, 2011
Interest expense	$	1,371		1,478			$	4,350		4,475
Deferred financing cost	141			149			428			461
Interest income	(11		)	(98		)	(55		)	(403		)
Less: amount capitalized for capital projects	(187		)	(27		)	(187		)	(446		)
Total interest expense, net	$	1,314		$	1,502		$	4,536		$	4,087

XML

Share-Based Compensation (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2012 BoardMembers	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Repurchase Program, Authorized Amount		$ 50,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value				$ 20.41
Members of the Board of Directors	6
Stock Grants Expense		0	0	360,000	300,000
Stock Repurchased During Period, Shares		150,000
Treasury Stock Acquired, Average Cost Per Share		$ 48.37
Payments for Repurchase of Common Stock		7,300,000		7,255,000	6,156,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Range of Shares, Minimum		0		0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Range of Shares as Caluclated Using Performance Indicators, Maximum		200.00%		200.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		39,683
Stock Granted During Period, Value, Share-based Compensation, Gross		800,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value		$ 50.12
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date		Mar. 30, 2022
Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,275
Stock Grants Expense	400,000
Performance Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		43,106
Stock Granted During Period, Value, Share-based Compensation, Gross		2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period		136,423
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		14,370
Stock Granted During Period, Value, Share-based Compensation, Gross		$ 700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value		$ 50.12

XML

Acquisitions (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Oct. 31, 2011

Kelatron Corporation [Member]

Sep. 30, 2012

AMT [Member]

Jul. 17, 2012

AMT [Member]

Jul. 17, 2012

AMT Labs Real Estate [Member]

Sep. 30, 2012

Customer Relationships [Member]

AMT [Member]

Rate

Sep. 30, 2012

Distributors [Member]

AMT [Member]

Rate

Sep. 30, 2012

Minimum [Member]

Customer Relationships [Member]

AMT [Member]

Sep. 30, 2012

Minimum [Member]

Developed Technology and Application Patents [Member]

AMT [Member]

Sep. 30, 2012

Minimum [Member]

Trade Names [Member]

AMT [Member]

Sep. 30, 2012

Minimum [Member]

Noncompete Agreements [Member]

AMT [Member]

Sep. 30, 2012

Maximum [Member]

Customer Relationships [Member]

AMT [Member]

Sep. 30, 2012

Maximum [Member]

Developed Technology and Application Patents [Member]

AMT [Member]

Sep. 30, 2012

Maximum [Member]

Trade Names [Member]

AMT [Member]

Sep. 30, 2012

Maximum [Member]

Noncompete Agreements [Member]

AMT [Member]

Business Acquisition [Line Items]

Acquired Finite Lived Intangible Asset, Useful Life

10 years

7 years

5 years

10 years

15 years

7 years

5 years

10 years

Business Acquisition, Cost of Acquired Entity, Purchase Price

$ 21,000,000

$ 28,000,000

Business Acquisition, Description of Acquired Entity

20 years

Business Acquisition, Purchase Price Allocation, Assets Acquired

27,000,000

Business Combination Valuation Assumption, Excess Earnings Method

15.50%

16.50%

Business Acquisition, Purchase Price Allocation, Property

7,500,000

Business Acquisition, Contingent Consideration, Potential Cash Payment

3,000,000

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset

1,000,000

Revenue, Net

$ 211,188,000

$ 202,102,000

$ 653,620,000

$ 601,327,000

$ 2,200,000

Business Combination Disclosure [Text Block]

Acquisitions

The Company has made two recent acquisitions in the bioactive mineral ingredients sector. Bioactive mineral ingredients are mineral based ingredients for food, beverage and dietary supplement end markets that are manufactured to be readily digestible. Historically, Innophos has enjoyed a strong position in “macronutrients,” minerals such as calcium, magnesium and potassium that are required in relatively large amounts for a balanced diet. The human diet also requires smaller quantities of a wide range of other minerals such as chromium, selenium, zinc and iron classified as “micronutrients.” The acquisitions described below have created a strong position for Innophos in micronutrient bioactive mineral ingredients to complement the Company's existing strength in macronutrients.

In October 2011, Innophos acquired privately held Kelatron Corporation in a transaction accounted for under the acquisition method of accounting for business combinations. Kelatron, based in Ogden, Utah, is a leading producer of bioactive mineral nutrients sold into the nutritional and dietary supplements markets. The acquisition had a purchase price of approximately $21 million in cash, subject to working capital adjustments, and was funded from our revolving line of credit. Under the acquisition method of accounting, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date. The reported consolidated financial condition and results of operations after completion of the acquisition reflect those fair values, and Kelatron's results of operations have been included in the consolidated financial statements from the date of acquisition. The purchase accounting for the acquisition has been closed and immaterial adjustments were recognized in the second quarter of 2012.

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. The combined purchase price was $27.0 million in cash, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity, plus a contingent payment arrangement.The arrangement provides for payments of up to $3.0 million if certain new market development opportunities, measured by adjusted revenue, are realized following the acquisition. The fair value of the contingent consideration arrangement has been preliminarily set at $1.0 million based on probability of achievement and recorded at net present value, making for a total purchase price of $28.0 million. The cash was funded from our revolving line of credit, as well as cash from operations.

During the three months ended September 30, 2012, the Company's consolidated results of operations included revenues of $2.2 million with an immaterial effect on net income attributable to AMT.

The preliminary AMT purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below (in thousands):

Cash	$	325
Accounts receivable	841
Inventory, including step up of $352	2,020
Other current assets	39
Property, plant and equipment	9,483
Goodwill	6,494
Intangible assets	9,830
Accounts payable	(377		)
Other current liabilities	(1,237		)
Total	$	27,418

The intangible assets acquired in the AMT purchase include the following (in thousands):

	Useful life (years)
Customer relationships	10-15	$	6,820
Developed technology	7	1,900
Tradename	5	930
Non-compete agreement	10	180
		$	9,830

The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition and will be included in the Specialty Phosphates US segment. The Company expects the goodwill created to be deductible for tax purposes. This transaction was treated as an asset purchase for U.S. federal tax purposes.

The customer relationships were valued based on the excess earnings method under the income approach which provides an estimate of the fair value based on a market participant. The after tax cash flows were discounted to present value using a 15.5% and 16.5% discount rate for direct customers and distributors, respectively.

Pro forma financial information (unaudited):

The following unaudited pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 and September 30, 2011 as if the acquisitions of Kelatron and AMT had been completed on January 1, 2011. The unaudited pro forma results do not reflect any material adjustments, operating efficiencies or potential cost savings which may result from the consolidation of operations.

	Three months ended				Nine months ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Revenues	$	211,382	$	208,117	$	660,380	$	622,214
Net income	$	16,902	$	18,199	$	60,500	$	66,070
Income per common share - Basic	$	0.78	$	0.84	$	2.77	$	3.04
Income per common share - Diluted	$	0.75	$	0.81	$	2.69	$	2.92

XML

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$ 36,571	$ 35,242
Accounts receivable, net	93,984	104,421
Inventories	154,240	169,728
Other current assets	78,493	75,316
Total current assets	363,288	384,707
Property, plant and equipment, net	185,876	187,421
Goodwill	68,047	61,587
Intangibles and other assets, net	60,069	53,300
Total assets	677,280	687,015
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt	4,000	4,000
Accounts payable, trade and other	35,861	32,640
Other current liabilities	48,508	71,609
Total current liabilities	88,369	108,249
Long-term debt	113,000	148,000
Other long-term liabilities	36,866	37,558
Total liabilities	238,235	293,807
Commitments and contingencies (note 12)
Stockholders’ equity:
Common stock, par value $.001 per share; authorized 100,000,000 shares; issued 22,020,597 and 21,770,641 shares and outstanding 21,719,965 and 21,620,119 shares	22	22
Paid-in capital	115,792	112,193
Common stock held in treasury, at cost (300,632 and 150,522 shares)	(13,411)	(6,156)
Retained earnings	340,961	292,144
Accumulated other comprehensive loss	(4,319)	(4,995)
Total stockholders’ equity	439,045	393,208
Total liabilities and stockholders’ equity	$ 677,280	$ 687,015

XML

Intangibles and Other Assets, net (Details) (USD $)								9 Months Ended						9 Months Ended
	Sep. 30, 2012	Jul. 17, 2012	Dec. 31, 2011	Sep. 30, 2012 Developed Technology and Application Patents [Member]	Dec. 31, 2011 Developed Technology and Application Patents [Member]	Sep. 30, 2012 Customer Relationships [Member]	Dec. 31, 2011 Customer Relationships [Member]	Sep. 30, 2012 Customer Relationships [Member] Minimum [Member]	Sep. 30, 2012 Customer Relationships [Member] Maximum [Member]	Sep. 30, 2012 Trade Names and License Agreements [Member]	Dec. 31, 2011 Trade Names and License Agreements [Member]	Sep. 30, 2012 Noncompete Agreements [Member]	Dec. 31, 2011 Noncompete Agreements [Member]	Sep. 30, 2012 Noncompete Agreements [Member] Minimum [Member]	Sep. 30, 2012 Noncompete Agreements [Member] Maximum [Member]	Sep. 30, 2012 Developed Technology Rights [Member] Minimum [Member]	Sep. 30, 2012 Developed Technology Rights [Member] Maximum [Member]	Sep. 30, 2012 Trade Names [Member] Minimum [Member]	Sep. 30, 2012 Trade Names [Member] Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization				$ 15,585,000	$ 13,980,000	$ 7,203,000	$ 5,956,000			$ 4,676,000	$ 4,246,000	$ 636,000	$ 568,000
Accumulated Amortization, Deferred Finance Costs	1,265,000		837,000
Finite-Lived Intangible Assets, Useful Life								7 years	20 years					5 years	10 years	5 years	15 years	5 years	20 years
Intangible Assets, Net (Excluding Goodwill)	49,870,000		43,390,000	24,305,000	24,010,000	18,907,000	13,333,000			6,474,000	5,974,000	184,000	73,000
Deferred Finance Costs, Net	1,563,000		1,991,000
Deferred Tax Assets, Net	5,768,000		5,450,000
Other Assets, Miscellaneous	2,868,000		2,469,000
Other Assets	10,199,000		9,910,000
Other Assets, Noncurrent	60,069,000		53,300,000
Acquired Finite-lived Intangible Asset, Amount		$ 9,830,000

XML

Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities
Net income	$ 60,798	$ 65,572
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	32,118	32,443
Amortization of deferred financing charges	428	461
Deferred income tax (benefit) provision	(1,545)	6,378
Deferred profit sharing	0	395
Share-based compensation	3,319	5,122
Changes in assets and liabilities:
Decrease (increase) in accounts receivable	11,278	(10,870)
Decrease (increase) in inventories	17,508	(34,747)
(Increase) decrease in other current assets	(3,138)	9,503
Increase (decrease) in accounts payable	2,844	(443)
(Decrease) increase in other current liabilities	(18,933)	4,731
Changes in other long-term assets and liabilities	(3,884)	(3,111)
Net cash provided from operating activities	100,793	75,434
Cash flows used for investing activities:
Capital expenditures	(15,997)	(27,247)
Investment in AMT	(27,093)	0
Net cash used for investing activities	(43,090)	(27,247)
Cash flows used for financing activities:
Proceeds from exercise of stock options	381	484
Long-term debt borrowings	15,000	0
Long-term debt repayments	(50,000)	(8,000)
Excess tax benefits from exercise of stock options	2,681	2,487
Common stock repurchases	(7,255)	(6,156)
Dividends paid	(17,181)	(14,517)
Net cash used for financing activities	(56,374)	(25,702)
Net change in cash	1,329	22,485
Cash and cash equivalents at beginning of period	35,242	63,706
Cash and cash equivalents at end of period	$ 36,571	$ 86,191

XML

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

For the three months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	144,664	$	41,222	$	25,302		$	—		$	211,188
Intersegment sales	370		14,087		57			(14,514		)	—
Total sales	$	145,034	$	55,309	$	25,359		$	(14,514	)	$	211,188
Operating income (b)	$	22,759	$	2,369	$	(542	)	$	—		$	24,586
Depreciation and amortization expense	$	5,732	$	3,670	$	1,160		$	—		$	10,562
For the three months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	130,850	$	48,601	$	22,651		$	—		$	202,102
Intersegment sales	284		14,841		132			(15,257		)	—
Total sales	$	131,134	$	63,442	$	22,783		$	(15,257	)	$	202,102
Operating income (c)	$	21,331	$	7,143	$	4,651		$	—		$	33,125
Depreciation and amortization expense	$	4,864	$	4,909	$	1,753		$	—		$	11,526
For the nine months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	432,528	$	139,951	$	81,141		$	—		$	653,620
Intersegment sales	1,218		45,082		320			(46,620		)	—
Total sales	$	433,746	$	185,033	$	81,461		$	(46,620	)	$	653,620
Operating income (a) (b)	$	70,262	$	17,156	$	1,590		$	—		$	89,008
Depreciation and amortization expense	$	17,280	$	11,233	$	3,605		$	—		$	32,118
For the nine months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	393,262	$	132,634	$	75,431		$	—		$	601,327
Intersegment sales	1,056		35,522		312			(36,890		)	—
Total sales	$	394,318	$	168,156	$	75,743		$	(36,890	)	$	601,327
Operating income (c)	$	77,613	$	12,358	$	16,593		$	—		$	106,564
Depreciation and amortization expense	$	14,897	$	12,814	$	4,732		$	—		$	32,443

(a) The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.

(b) The nine months ended September 30, 2012 includes $2.4 million of out of period cost in Mexico in GTSP & Other.

(c) The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Segment Reporting

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Segment Reporting [Text Block]

Segment Reporting

The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.

The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron and AMT are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.

For the three months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	144,664	$	41,222	$	25,302		$	—		$	211,188
Intersegment sales	370		14,087		57			(14,514		)	—
Total sales	$	145,034	$	55,309	$	25,359		$	(14,514	)	$	211,188
Operating income (b)	$	22,759	$	2,369	$	(542	)	$	—		$	24,586
Depreciation and amortization expense	$	5,732	$	3,670	$	1,160		$	—		$	10,562
For the three months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	130,850	$	48,601	$	22,651		$	—		$	202,102
Intersegment sales	284		14,841		132			(15,257		)	—
Total sales	$	131,134	$	63,442	$	22,783		$	(15,257	)	$	202,102
Operating income (c)	$	21,331	$	7,143	$	4,651		$	—		$	33,125
Depreciation and amortization expense	$	4,864	$	4,909	$	1,753		$	—		$	11,526
For the nine months ended September 30, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	432,528	$	139,951	$	81,141		$	—		$	653,620
Intersegment sales	1,218		45,082		320			(46,620		)	—
Total sales	$	433,746	$	185,033	$	81,461		$	(46,620	)	$	653,620
Operating income (a) (b)	$	70,262	$	17,156	$	1,590		$	—		$	89,008
Depreciation and amortization expense	$	17,280	$	11,233	$	3,605		$	—		$	32,118
For the nine months ended September 30, 2011	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other			Eliminations			Total
Sales	$	393,262	$	132,634	$	75,431		$	—		$	601,327
Intersegment sales	1,056		35,522		312			(36,890		)	—
Total sales	$	394,318	$	168,156	$	75,743		$	(36,890	)	$	601,327
Operating income (c)	$	77,613	$	12,358	$	16,593		$	—		$	106,564
Depreciation and amortization expense	$	14,897	$	12,814	$	4,732		$	—		$	32,443

(a) The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.

(b) The nine months ended September 30, 2012 includes $2.4 million of out of period cost in Mexico in GTSP & Other.

(c) The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2012

Business Combinations [Abstract]

Schedule of Purchase Price Allocation [Table Text Block]

The preliminary AMT purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below (in thousands):

Cash	$	325
Accounts receivable	841
Inventory, including step up of $352	2,020
Other current assets	39
Property, plant and equipment	9,483
Goodwill	6,494
Intangible assets	9,830
Accounts payable	(377		)
Other current liabilities	(1,237		)
Total	$	27,418

The intangible assets acquired in the AMT purchase include the following (in thousands):

	Useful life (years)
Customer relationships	10-15	$	6,820
Developed technology	7	1,900
Tradename	5	930
Non-compete agreement	10	180
		$	9,830

Business Acquisition, Pro Forma Information [Table Text Block]

	Three months ended				Nine months ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Revenues	$	211,382	$	208,117	$	660,380	$	622,214
Net income	$	16,902	$	18,199	$	60,500	$	66,070
Income per common share - Basic	$	0.78	$	0.84	$	2.77	$	3.04
Income per common share - Diluted	$	0.75	$	0.81	$	2.69	$	2.92

XML

Basis of Statement Presentation (Policies)

9 Months Ended

Sep. 30, 2012

Basis of Statement Presentation: [Abstract]

Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block]

Out of Period Adjustments

During the second quarter of fiscal 2012, we identified certain adjustments in our financial statements related to 2011 through the first quarter of fiscal 2012. We corrected the items during the second quarter of fiscal 2012, which had the effect of increasing cost of goods sold by $3.9 million, and decreasing net income by $2.6 million. The impact of these items for the nine months ended September 30, 2012 increased cost of goods sold by $2.4 million and decreased net income by $1.6 million. These prior period adjustments are not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. These adjustments are also not expected to be material to the full year 2012 financial statements.

Description of Business and Principles of Consolidation [Policy Text Block]

1. Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2011 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2011 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

XML

Statements of Stockholders' Equity (Unaudited) (USD $) In Thousands, except Share data	Total USD ($)	Number of Common Shares	Common Stock USD ($)	Retained Earnings USD ($)	Paid-in Capital USD ($)	Accumulated Other Comprehensive Income(Loss) USD ($)
Balance at Dec. 31, 2010	$ 330,716		$ 21	$ 227,752	$ 106,032	$ (3,089)
Balance, shares at Dec. 31, 2010		21,464,000
Net income	86,522			86,522
Other comprehensive income (loss), net of tax	(1,906)					(1,906)
Proceeds from stock award exercises and issuances, shares		300,000
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options			1
Proceeds from stock award exercises and issuances	(2,599)				(2,600)
Issuance of annual retainer stock to Board of Directors, shares		7,000
Share-based compensation	6,250				6,250
Excess tax benefits from exercise of stock options	2,511				2,511
Common stock repurchases, shares		(151,000)
Common stock repurchases	(6,156)
Dividends declared	(22,130)			(22,130)
Balance at Dec. 31, 2011	393,208		22	292,144	106,037	(4,995)
Balance, shares at Dec. 31, 2011	21,620,119	21,620,000
Net income	60,798			60,798
Other comprehensive income (loss), net of tax	676					676
Proceeds from stock award exercises and issuances, shares		250,000
Proceeds from stock award exercises and issuances	(2,401)				(2,401)
Share-based compensation	3,319				3,319
Excess tax benefits from exercise of stock options	2,681				2,681
Common stock repurchases, shares		(150,000)
Common stock repurchases	(7,255)				(7,255)
Dividends declared	(11,981)			(11,981)
Balance at Sep. 30, 2012	$ 439,045		$ 22	$ 340,961	$ 102,381	$ (4,319)
Balance, shares at Sep. 30, 2012	21,719,965	21,720,000

XML

Condensed Consolidated Balance Sheets (Unaudited) Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Common Stock, Shares, Issued	22,020,597	21,770,641
Common Stock, Shares, Outstanding	21,719,965	21,620,119
Treasury Stock, Shares	300,632	150,522
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000

XML

Debt and Interest

9 Months Ended

Sep. 30, 2012

Short-term Borrowings, Long-Term Debt, and Interest Expense: [Abstract]

Debt and Interest

Short-term Borrowings, Long-Term Debt, and Interest Expense

Short-term borrowings and long-term debt consist of the following:

	September 30, 2012		December 31, 2011
Term loan due 2015	$	92,000	$	95,000
Revolver borrowings under the credit facility	25,000		57,000
Total borrowings	$	117,000	$	152,000
Less current portion	4,000		4,000
Long-term debt	$	113,000	$	148,000

The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $125.0 million, including a $20.0 million letter of credit sub-facility, all maturing on August 26, 2015. Prepayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on December 31, 2010.

As of September 30, 2012, $92.0 million was outstanding under the Term Loan and $25.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, level 2 input within the fair value hierarchy, with total availability at $98.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 4.1%.

In the third quarter of 2010 the Company entered into an interest rate swap with an original notional amount of $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 1.994% plus the applicable margin on the debt expiring in August 2015. The Company exercised its right to cancel the interest rate swap with no fee on September 28, 2012.

We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.

Total interest paid by the Company for all indebtedness for the nine months ended September 30, 2012 and September 30, 2011 was $4,355 and $4,504.

As of September 30, 2012, the Company was in full compliance with all debt covenant requirements.

Interest expense, net consists of the following:

	Three months ended						Nine months ended
	September 30, 2012			September 30, 2011			September 30, 2012			September 30, 2011
Interest expense	$	1,371		1,478			$	4,350		4,475
Deferred financing cost	141			149			428			461
Interest income	(11		)	(98		)	(55		)	(403		)
Less: amount capitalized for capital projects	(187		)	(27		)	(187		)	(446		)
Total interest expense, net	$	1,314		$	1,502		$	4,536		$	4,087

XML

Document and Entity Information Document	9 Months Ended
	Sep. 30, 2012
Document Information [Line Items]
Entity Registrant Name	Innophos Holdings, Inc.
Trading Symbol	IPHS
Entity Central Index Key	0001364099
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding	21,719,965
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

XML

Other Long-Term Liabilities

9 Months Ended

Sep. 30, 2012

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Other Liabilities Disclosure [Text Block]

Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	September 30, 2012		December 31, 2011
Deferred income taxes	$	23,761	$	24,308
Pension and post retirement liabilities (U.S. and Canada only)	6,290		6,185
Environmental liabilities	1,100		1,100
Profit sharing and post employment liabilities	4,478		3,795
Other liabilities	1,237		2,170
	$	36,866	$	37,558

XML

Consolidated Statements of Comprehensive Income (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012		Sep. 30, 2011
Statement of Other Comprehensive Income [Abstract]
Net sales	$ 211,188	$ 202,102	$ 653,620		$ 601,327
Cost of goods sold	168,409	152,872	512,605		445,604
Gross profit	42,779	49,230	141,015		155,723
Operating expenses:
Selling, general and administrative	17,417	15,343	49,687		46,954
Research & development expenses	776	762	2,320		2,205
Total operating expenses	18,193	16,105	52,007		49,159
Operating income	24,586	33,125	89,008	[1]	106,564	[2]
Interest expense, net	1,314	1,502	4,536		4,087
Foreign exchange losses (gains)	(1,800)	1,459	(2,199)		2,017
Income before income taxes	25,072	30,164	86,671		100,460
Provision for income taxes	8,366	11,307	25,873		34,888
Net income	16,706	18,857	60,798		65,572
Net income attributable to common shareholders	16,695	18,857	60,758		65,572
Income per share:
Basic	$ 0.77	$ 0.87	$ 2.79		$ 3.02
Diluted	$ 0.74	$ 0.84	$ 2.70		$ 2.90
Weighted average shares outstanding:
Basic	21,807,013	21,691,892	21,804,415		21,719,580
Diluted	22,500,262	22,557,661	22,519,360		22,604,845
Other comprehensive (loss) income, net of tax:
Change in interest rate swaps, (net of tax $136, ($230), $312 and ($589))	221	(375)	509		(962)
Change in pension and post-retirement plans, (net of tax ($18), $76, $70 and $319)	(80)	223	167		652
Other comprehensive income (loss), net of tax	141	(152)	676		(310)
Comprehensive income	$ 16,847	$ 18,705	$ 61,474		$ 65,262

[1] The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.

[2] The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Stockholders' Equity / Share-Based Compensation

9 Months Ended

Sep. 30, 2012

Share-based Compensation [Abstract]

Share-Based Compensation

Stockholders’ Equity / Stock-Based Compensation

Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:

• Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.

• Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.

Restricted Stock

On March 30, 2012 there were a total of 14,370 restricted shares granted to certain employees with a fair value of $0.7 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $50.12. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.

Stock Options

On March 30, 2012 the Company granted 39,683 non-qualified stock options at an exercise price of $50.12 per share to certain employees with a fair value of $0.8 million. The non-qualified stock options vest annually over three years with a March 30, 2022 expiration date.

The fair value of the options granted during 2012 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility	53.2		%
Dividend yield	2.4		%
Risk-free interest rate	1.3		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	20.41

For the 2012 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.

Performance Share Awards

On March 30, 2012, the Company granted 43,106 performance shares to certain employees with a fair value of $2.2 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.

In connection with the vesting of the performance share awards issued in 2009, the Company issued 136,423 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2012.

Stock Grants

In May 2012 the six external members of the Board of Directors were each granted 1,275 shares of the Company's common stock with an aggregated fair value of $0.4 million which immediately vested as part of their director fees.

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended				Nine Months Ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Stock options	$	291	$	288	$	1,147	$	1,225
Restricted stock	57		—		180		6
Performance shares	643		806		1,632		3,591
Stock grants	—		—		360		300
Total share-based compensation expense	$	991	$	1,094	$	3,319	$	5,122

During 2011 the Board of Directors authorized a repurchase program for Company common stock of up to $50 million. Under the program, shares will be repurchased from time to time at management's discretion, either through open market transactions, block purchases, private transactions or other means and will be funded through existing liquidity and cash from operations. A five year time limit has been set for the expiration of the program as initially structured. The timing of repurchases and the exact number of shares of common stock to be purchased will depend upon market conditions and other factors. However, annual repurchase amounts are expected at a minimum to be sufficient to reduce significantly, or eliminate, earnings per share dilution caused by shares issued upon the exercise of stock options and in connection with other equity based compensation plans. Treasury stock is recognized at the cost to reacquire the shares. During the third quarter of 2012, the Company repurchased 150,000 shares of its common stock on the open market at an average price of $48.37 per share or $7.3 million.

XML

Dividends

9 Months Ended

Sep. 30, 2012

Dividends [Abstract]

Dividends [Text Block]

Dividends

The following is the dividend activity for the three and nine months ended September 30, 2012 and September 30, 2011:

	Three Months Ended				Nine Months Ended
	September 30				September 30
	2012		2011		2012		2011
Dividends declared – per share	$	—	$	0.25	$	0.54	$	0.75
Dividends declared – aggregate	—		5,442		11,776		16,309
Dividends paid – per share	0.27		0.25		0.79		0.67
Dividends paid – aggregate	5,891		5,442		17,181		14,517

We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.

On October 26, 2012, the Company's Board of Directors declared an increase to its dividend to $0.35 per share to be paid on November 30, 2012 to shareholders of record on November 16, 2012.

XML

Acquisitions

9 Months Ended

Sep. 30, 2012

Business Acquisition [Line Items]

Business Combination Disclosure [Text Block]

Acquisitions

The Company has made two recent acquisitions in the bioactive mineral ingredients sector. Bioactive mineral ingredients are mineral based ingredients for food, beverage and dietary supplement end markets that are manufactured to be readily digestible. Historically, Innophos has enjoyed a strong position in “macronutrients,” minerals such as calcium, magnesium and potassium that are required in relatively large amounts for a balanced diet. The human diet also requires smaller quantities of a wide range of other minerals such as chromium, selenium, zinc and iron classified as “micronutrients.” The acquisitions described below have created a strong position for Innophos in micronutrient bioactive mineral ingredients to complement the Company's existing strength in macronutrients.

In October 2011, Innophos acquired privately held Kelatron Corporation in a transaction accounted for under the acquisition method of accounting for business combinations. Kelatron, based in Ogden, Utah, is a leading producer of bioactive mineral nutrients sold into the nutritional and dietary supplements markets. The acquisition had a purchase price of approximately $21 million in cash, subject to working capital adjustments, and was funded from our revolving line of credit. Under the acquisition method of accounting, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date. The reported consolidated financial condition and results of operations after completion of the acquisition reflect those fair values, and Kelatron's results of operations have been included in the consolidated financial statements from the date of acquisition. The purchase accounting for the acquisition has been closed and immaterial adjustments were recognized in the second quarter of 2012.

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. The combined purchase price was $27.0 million in cash, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity, plus a contingent payment arrangement.The arrangement provides for payments of up to $3.0 million if certain new market development opportunities, measured by adjusted revenue, are realized following the acquisition. The fair value of the contingent consideration arrangement has been preliminarily set at $1.0 million based on probability of achievement and recorded at net present value, making for a total purchase price of $28.0 million. The cash was funded from our revolving line of credit, as well as cash from operations.

During the three months ended September 30, 2012, the Company's consolidated results of operations included revenues of $2.2 million with an immaterial effect on net income attributable to AMT.

The preliminary AMT purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below (in thousands):

Cash	$	325
Accounts receivable	841
Inventory, including step up of $352	2,020
Other current assets	39
Property, plant and equipment	9,483
Goodwill	6,494
Intangible assets	9,830
Accounts payable	(377		)
Other current liabilities	(1,237		)
Total	$	27,418

The intangible assets acquired in the AMT purchase include the following (in thousands):

	Useful life (years)
Customer relationships	10-15	$	6,820
Developed technology	7	1,900
Tradename	5	930
Non-compete agreement	10	180
		$	9,830

The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition and will be included in the Specialty Phosphates US segment. The Company expects the goodwill created to be deductible for tax purposes. This transaction was treated as an asset purchase for U.S. federal tax purposes.

The customer relationships were valued based on the excess earnings method under the income approach which provides an estimate of the fair value based on a market participant. The after tax cash flows were discounted to present value using a 15.5% and 16.5% discount rate for direct customers and distributors, respectively.

Pro forma financial information (unaudited):

The following unaudited pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 and September 30, 2011 as if the acquisitions of Kelatron and AMT had been completed on January 1, 2011. The unaudited pro forma results do not reflect any material adjustments, operating efficiencies or potential cost savings which may result from the consolidation of operations.

	Three months ended				Nine months ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Revenues	$	211,382	$	208,117	$	660,380	$	622,214
Net income	$	16,902	$	18,199	$	60,500	$	66,070
Income per common share - Basic	$	0.78	$	0.84	$	2.77	$	3.04
Income per common share - Diluted	$	0.75	$	0.81	$	2.69	$	2.92

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Tax Expense (Benefit) [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The effective income tax rate on income before taxes was approximately 30% for the nine months ended September 30, 2012 compared to approximately 35% for the comparable period in 2011. The variance in the effective tax rate is primarily due to the recording of an indemnity receivable related to the Mexican CNA Water Tax Claims (see note 12, Mexican CNA Water Tax Claims) being recorded as a discrete item for income tax provision purposes in the first quarter of 2012.

The Company does not have any material uncertain income tax positions in accordance with ASC 740-10-25. If any material uncertain tax positions did arise, the Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2009. As of September 30, 2012, our subsidiary, Innophos Mexicana requested a refund of $2.4 million for the 2009 tax year which is being disputed by the Mexican tax authorities. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. On April 27, 2012, Innophos Canada filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. Other than the assessments mentioned above, as of September 30, 2012, no significant adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.

Income taxes paid were $36,931 and $17,543 for the nine months ended September 30, 2012 and September 30, 2011, respectively.

XML

Intangibles and Other Assets, net

9 Months Ended

Sep. 30, 2012

Intangibles and Other Assets, net: [Abstract]

Intangibles and Other Assets, net [Text Block]

Intangibles and Other Assets, net

Intangibles and other assets consist of the following:

	Useful life (years)	September 30, 2012		December 31, 2011
Developed technology and application patents, net of accumulated amortization of $15,585 for 2012 and $13,980 for 2011	7-20	$	24,305	$	24,010
Customer relationships, net of accumulated amortization of $7,203 for 2012 and $5,956 for 2011	5-15	18,907		13,333
Tradenames and license agreements, net of accumulated amortization of $4,676 for 2012 and $4,246 for 2011	5-20	6,474		5,974
Non-compete agreements, net of accumulated amortization of $636 for 2012 and $568 for 2011	5-10	184		73
Total intangibles		$	49,870	$	43,390
Deferred financing costs, net of accumulated amortization of $1,265 for 2012 and $837 for 2011 (see note 9)		$	1,563	$	1,991
Deferred income taxes		5,768		5,450
Other Assets		2,868		2,469
Total other assets		$	10,199	$	9,910
		$	60,069	$	53,300

XML

Inventories

9 Months Ended

Sep. 30, 2012

Inventory Disclosure [Abstract]

Inventories [Text Block]

Inventories

Inventories consist of the following:

	September 30, 2012		December 31, 2011
Raw materials	$	39,454	$	44,937
Finished products	105,878		116,488
Spare parts	8,908		8,303
	$	154,240	$	169,728

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of September 30, 2012 and December 31, 2011 were $11,849 and $9,911, respectively.

XML

Other Current Assets

9 Months Ended

Sep. 30, 2012

Other Current Assets: [Abstract] [Abstract]

Other Current Assets [Text Block]

Other Current Assets

Other current assets consist of the following:

	September 30, 2012		December 31, 2011
Rhodia indemnity receivable for CNA water tax claims (see note 12)	$	—	$	13,571
Creditable taxes (value added taxes)	31,957		20,473
Vendor inventory deposits (prepaid)	12,036		19,671
Prepaid income taxes	17,324		4,829
Other prepaids	2,397		2,585
Deferred income taxes	10,348		10,347
Other	4,431		3,840
	$	78,493	$	75,316

XML

Other Current Liabilities

9 Months Ended

Sep. 30, 2012

Other Liabilities, Current [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Other Current Liabilities

Other current liabilities consist of the following:

	September 30, 2012		December 31, 2011
CNA water tax claims (see Note 12)	$	10,592	$	31,523
Payroll related	10,820		11,708
Taxes	9,292		5,885
Benefits and pensions	5,884		7,717
Freight and rebates	4,962		4,418
Dividends payable	—		5,405
Other	6,958		4,953
	$	48,508	$	71,609

XML

Pension Plans and Postretirement Benefits (Tables)

9 Months Ended

Sep. 30, 2012

US [Member]

Pension Plans and Postretirement Benefits [Line Items]

Schedule of Net Benefit Costs [Table Text Block]

Net periodic benefit expense for the United States plans:

	For the three months ended September 30, 2012									For the three months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	81		$	81		$	—		$	72		$	72
Interest cost	28			34			62			27			37			64
Expected return on assets	(28		)	—			(28		)	(18		)	—			(18		)
Amortization of
prior service cost	—			33			33			—			32			32
unrecognized (gain) loss	4			(7		)	(3		)	—			(15		)	(15		)
Net periodic cost	$	4		$	141		$	145		$	9		$	126		$	135
	For the nine months ended September 30, 2012									For the nine months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	243		$	243		$	—		$	219		$	219
Interest cost	82			106			188			83			111			194
Expected return on assets	(82		)	—			(82		)	(54		)	—			(54		)
Amortization of
prior service cost	—			97			97			—			99			99
unrecognized (gain) loss	10			(21		)	(11		)	—			(46		)	(46		)
Net periodic cost	$	10		$	425		$	435		$	29		$	383		$	412

Canada [Member]

Pension Plans and Postretirement Benefits [Line Items]

Schedule of Net Benefit Costs [Table Text Block]

Net periodic benefit expense for the Canadian plans:

	For the three months ended September 30, 2012								For the three months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	85		$	21	$	106		$	69		$	17		$	86
Interest cost	151			26		177			142			23			165
Expected return on assets	(236		)	—		(236		)	(238		)	—			(238		)
Amortization of
actuarial loss (gain)	65			11		76			—			7			7
prior service cost	26			—		26			26			—			26
net transition obligation	—			7		7			40			10			50
Exchange rate changes	122			22		144			(46		)	(10		)	(56		)
Net periodic cost	$	213		$	87	$	300		$	(7	)	$	47		$	40
	For the nine months ended September 30, 2012								For the nine months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	253		$	61	$	314		$	211		$	51		$	262
Interest cost	451			74		525			433			71			504
Expected return on assets	(706		)	—		(706		)	(726		)	—			(726		)
Amortization of
actuarial loss (gain)	195			35		230			—			23			23
prior service cost	78			—		78			80			—			80
net transition obligation	—			23		23			124			30			154
Exchange rate changes	142			29		171			140			(35		)	105
Net periodic cost	$	413		$	222	$	635		$	262		$	140		$	402

XML

Pension Plans and Postretirement Benefits (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	$ 81,000	$ 72,000	$ 243,000	$ 219,000
Defined Benefit Plan, Interest Cost	62,000	64,000	188,000	194,000
Defined Benefit Plan, Expected Return on Plan Assets	(28,000)	(18,000)	(82,000)	(54,000)
Defined Benefit Plan, Amortization of Gains (Losses)	(3,000)	(15,000)	(11,000)	(46,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	33,000	32,000	97,000	99,000
Defined Benefit Plan, Net Periodic Benefit Cost	145,000	135,000	435,000	412,000
Planned Employer Contributions	200,000		200,000
Defined Contribution Plan, Cost Recognized	3,000,000
Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	106,000	86,000	314,000	262,000
Defined Benefit Plan, Interest Cost	177,000	165,000	525,000	504,000
Defined Benefit Plan, Expected Return on Plan Assets	(236,000)	(238,000)	(706,000)	(726,000)
Defined Benefit Plan, Amortization of Gains (Losses)	76,000	7,000	230,000	23,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	26,000	26,000	78,000	80,000
Defined Benefit Plan, Other Costs	7,000	50,000	23,000	154,000
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	144,000	(56,000)	171,000	105,000
Defined Benefit Plan, Net Periodic Benefit Cost	300,000	40,000	635,000	402,000
Planned Employer Contributions	200,000		200,000
Employer Contributions			600,000
Pension Benefits [Member] | US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0	0	0
Defined Benefit Plan, Interest Cost	28,000	27,000	82,000	83,000
Defined Benefit Plan, Expected Return on Plan Assets	(28,000)	(18,000)	(82,000)	(54,000)
Defined Benefit Plan, Amortization of Gains (Losses)	4,000	0	10,000	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	4,000	9,000	10,000	29,000
Pension Benefits [Member] | Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	85,000	69,000	253,000	211,000
Defined Benefit Plan, Interest Cost	151,000	142,000	451,000	433,000
Defined Benefit Plan, Expected Return on Plan Assets	(236,000)	(238,000)	(706,000)	(726,000)
Defined Benefit Plan, Amortization of Gains (Losses)	65,000	0	195,000	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	26,000	26,000	78,000	80,000
Defined Benefit Plan, Other Costs	0	40,000	0	124,000
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	122,000	(46,000)	142,000	140,000
Defined Benefit Plan, Net Periodic Benefit Cost	213,000	(7,000)	413,000	262,000
Other Benefits [Member] | US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	81,000	72,000	243,000	219,000
Defined Benefit Plan, Interest Cost	34,000	37,000	106,000	111,000
Defined Benefit Plan, Expected Return on Plan Assets	0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	(7,000)	(15,000)	(21,000)	(46,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	33,000	32,000	97,000	99,000
Defined Benefit Plan, Net Periodic Benefit Cost	141,000	126,000	425,000	383,000
Other Benefits [Member] | Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	21,000	17,000	61,000	51,000
Defined Benefit Plan, Interest Cost	26,000	23,000	74,000	71,000
Defined Benefit Plan, Expected Return on Plan Assets	0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	11,000	7,000	35,000	23,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Other Costs	7,000	10,000	23,000	30,000
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	22,000	(10,000)	29,000	(35,000)
Defined Benefit Plan, Net Periodic Benefit Cost	$ 87,000	$ 47,000	$ 222,000	$ 140,000

XML

Pension Plans and Postretirement Benefits

9 Months Ended

Sep. 30, 2012

Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

	For the three months ended September 30, 2012									For the three months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	81		$	81		$	—		$	72		$	72
Interest cost	28			34			62			27			37			64
Expected return on assets	(28		)	—			(28		)	(18		)	—			(18		)
Amortization of
prior service cost	—			33			33			—			32			32
unrecognized (gain) loss	4			(7		)	(3		)	—			(15		)	(15		)
Net periodic cost	$	4		$	141		$	145		$	9		$	126		$	135
	For the nine months ended September 30, 2012									For the nine months ended September 30, 2011
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	243		$	243		$	—		$	219		$	219
Interest cost	82			106			188			83			111			194
Expected return on assets	(82		)	—			(82		)	(54		)	—			(54		)
Amortization of
prior service cost	—			97			97			—			99			99
unrecognized (gain) loss	10			(21		)	(11		)	—			(46		)	(46		)
Net periodic cost	$	10		$	425		$	435		$	29		$	383		$	412

In April 2012, Innophos contributed approximately $0.2 million to its U.S. defined benefit pension plan to satisfy the full year 2012 minimum contribution requirements.

Innophos made its entire cash contribution of $3.0 million for the U.S. defined contribution plan during the first quarter of 2012 for the plan year 2011.

Net periodic benefit expense for the Canadian plans:

	For the three months ended September 30, 2012								For the three months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	85		$	21	$	106		$	69		$	17		$	86
Interest cost	151			26		177			142			23			165
Expected return on assets	(236		)	—		(236		)	(238		)	—			(238		)
Amortization of
actuarial loss (gain)	65			11		76			—			7			7
prior service cost	26			—		26			26			—			26
net transition obligation	—			7		7			40			10			50
Exchange rate changes	122			22		144			(46		)	(10		)	(56		)
Net periodic cost	$	213		$	87	$	300		$	(7	)	$	47		$	40
	For the nine months ended September 30, 2012								For the nine months ended September 30, 2011
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	253		$	61	$	314		$	211		$	51		$	262
Interest cost	451			74		525			433			71			504
Expected return on assets	(706		)	—		(706		)	(726		)	—			(726		)
Amortization of
actuarial loss (gain)	195			35		230			—			23			23
prior service cost	78			—		78			80			—			80
net transition obligation	—			23		23			124			30			154
Exchange rate changes	142			29		171			140			(35		)	105
Net periodic cost	$	413		$	222	$	635		$	262		$	140		$	402

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.6 million during the nine months ended September 30, 2012. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.2 million during the remainder of 2012.

XML

Dividends (Tables)

9 Months Ended

Sep. 30, 2012

Dividends [Abstract]

Schedule of Dividends Payable [Table Text Block]

The following is the dividend activity for the three and nine months ended September 30, 2012 and September 30, 2011:

	Three Months Ended				Nine Months Ended
	September 30				September 30
	2012		2011		2012		2011
Dividends declared – per share	$	—	$	0.25	$	0.54	$	0.75
Dividends declared – aggregate	—		5,442		11,776		16,309
Dividends paid – per share	0.27		0.25		0.79		0.67
Dividends paid – aggregate	5,891		5,442		17,181		14,517

XML

Income Taxes - Narratives (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012 Rate	Mar. 31, 2011 Rate	Sep. 30, 2012	Sep. 30, 2011
Income Tax Examination [Line Items]
Effective Income Tax Rate, Continuing Operations	30.00%	35.00%
Income Taxes Paid			$ 36,931,000	$ 17,543,000
Mexico [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Disputed Refund Requested from Taxing Authority	2,400,000		2,400,000
Canada [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	4,000,000		$ 4,000,000

XML

Share-Based Compensation - Schedule of Compensation Expense (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Share-based Compensation [Abstract]
Stock options	$ 291	$ 288	$ 1,147	$ 1,225
Restricted stock	57	0	180	6
Performance shares	643	806	1,632	3,591
Stock Grants Expense	0	0	360	300
Total stock-based compensation expense	$ 991	$ 1,094	$ 3,319	$ 5,122

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Mar. 31, 2011	Sep. 30, 2012	Sep. 30, 2011
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	$ 136	$ (230)	$ 312	$ (589)
Other Comprehensive Income (Loss) Pension and Post-Retirement Plans Tax Effect Period Increase Decrease	$ (18)	$ 76	$ 70	$ 319

XML

Earnings Per Share (EPS)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Earnings Per Share (EPS)

Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended					Nine Months Ended
	September 30, 2012			September 30, 2011		September 30, 2012			September 30, 2011
Net income	$	16,706		$	18,857	$	60,798		$	65,572
Less: earnings attributable to unvested shares	(11		)	—		(40		)	—
Net income available to common shareholders	$	16,695		$	18,857	$	60,758		$	65,572
Weighted average number of common and potential common shares outstanding:
Basic number of common shares outstanding	21,807,013			21,691,892		21,804,415			21,719,580
Dilutive effect of stock equivalents	693,249			865,769		714,945			885,265
Diluted number of weighted average common shares outstanding	22,500,262			22,557,661		22,519,360			22,604,845
Earnings per common share:
Earnings per common share—Basic	$	0.77		$	0.87	$	2.79		$	3.02
Earnings per common share—Diluted	$	0.74		$	0.84	$	2.70		$	2.90
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	387,878			422,734		366,182			403,238

XML

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended				Nine Months Ended
	September 30, 2012		September 30, 2011		September 30, 2012		September 30, 2011
Stock options	$	291	$	288	$	1,147	$	1,225
Restricted stock	57		—		180		6
Performance shares	643		806		1,632		3,591
Stock grants	—		—		360		300
Total share-based compensation expense	$	991	$	1,094	$	3,319	$	5,122

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The fair value of the options granted during 2012 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility	53.2		%
Dividend yield	2.4		%
Risk-free interest rate	1.3		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	20.41

XML

Earnings Per Share (EPS) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Earnings Per Share Reconciliation [Abstract]
Net income	$ 16,706	$ 18,857	$ 60,798	$ 65,572	$ 86,522
Less: earnings attributable to unvested shares	(11)	0	(40)	0
Net income available to common shareholders	$ 16,695	$ 18,857	$ 60,758	$ 65,572
Basic number of common shares, outstanding	21,807,013	21,691,892	21,804,415	21,719,580
Dilutive effect of stock equivalents	693,249	865,769	714,945	885,265
Dilutived number of weighted average common shares outstanding	22,500,262	22,557,661	22,519,360	22,604,845
Earnings per common share - Basic	$ 0.77	$ 0.87	$ 2.79	$ 3.02
Earnings per common share - Diluted	$ 0.74	$ 0.84	$ 2.70	$ 2.90
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	387,878	422,734	366,182	403,238

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

Commitments and Contingencies

Environmental

The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Liabilities for environmental matters are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.

Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of September 30, 2012.

Litigation

2008 RCRA Civil Enforcement – Geismar, Louisiana plant

Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.

Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.

In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is ready for commissioning and operation once appropriate agreements are reached with the Government Parties and PCS.

We and PCS also have initiated joint efforts to explore possible technical solutions to remaining concerns of the Government Parties, including Raffinate treatment. To date, treatment techniques for Raffinate have not yet been fully evaluated from a technological or cost standpoint. Based upon work so far, there appears to be at least one technically viable approach, but it has yet to be fully evaluated.

Even though the companies have conducted substantial technical work in an attempt to develop a feasible approach to address regulatory concerns, we cannot guarantee that our technical efforts will be successful, whether either party would be willing to implement solutions at what cost allocation or, depending on those factors and the Government Parties' position, whether this matter will be settled or will require litigation. Should litigation become necessary to defend our operations at Geismar as compliant with environmental laws and regulations or with PCS as to cost responsibility, no assurance can be given as to its outcome.

Based upon advice of our environmental counsel, we have determined that the risk of an effort by the Government Parties to shut down our Geismar plant or PCS's Geismar plant from which we obtain the green acid raw material is remote. In addition, we have concluded that the contingent liability arising from compliance costs for this matter as discussed above is neither remote nor probable, but is reasonably possible. On the assumption that “deep well injection” at the site is ultimately employed or required as the technologically acceptable approach for Raffinate, based on preliminary cost estimates to date, we estimate this technical approach to range from approximately $10 to $16 million.

Mexican CNA Water Tax Claims - 2005-2008

In January 2012, Fosfatados was served with CNA resolutions claiming higher water fees, surcharges and penalties for 2005 through 2008 for the total amount of approximately $10.6 million at current exchange rates (net of regulatory discounts), for which the Company has recorded an accrual. The Company has timely contested the resolutions in Mexican Courts and posted security for the amount claimed by granting liens, in accordance with Mexican law, on specified production assets located at its Coatzacoalcos plant.

Other Legal Matters

In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.

In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters currently represent contingent liabilities that are not material. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.